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1. ETIOLOGY 
Actinobacillus pleuropneumoniae (A. pleuropneumoniae) is an obligate parasite of the porcine 
respiratory tract (Taylor, 1999).  The bacterium is a small, Gram-negative capsulated rod with 
typical coccobacillary morphology (Nicolet, 1992).  Based on nicotinamide adenine 
dinucleotide (NAD) requirements, A. pleuropneumoniae can be divided into 2 biotypes.  
Biotype 1 strains are NAD-dependent whereas biotype 2 strains are NAD-independent.  So 
far, 15 serotypes have been described (Blackall et al., 2002) although serotypes 1 and 5 are 
subdivided into 1a and 1b and 5a and 5b, respectively (Jolie et al., 1994; Nielsen, 1986; 
Nielsen et al, 1997).  All serotypes are haemolytic and produce a positive CAMP (Christie, 
Atkins, Munch-Peterson) reaction with beta-haemolytic Staphylococcus aureus (Taylor, 
1999).  The incomplete haemolysin zone induced by the ß-toxin is converted in a complete 
zone of haemolysis around the A. pleuropneumoniae colony.  Four toxins are produced: ApxI, 
II, III and IV (Dom et al., 1994a ; Frey et al., 1993 ; Frey et al., 1994 ; Jansen, 1994; Kamp et 
al., 1991 ; Schaller et al., 1999).  Serotyping is mainly based on capsular antigens.  
Furthermore, the serotypes have different lipopolysaccharide (LPS) composition, except that 
serotypes 1, 9 and 11, serotypes 3, 6 and 8 and serotypes 4 and 7 have common epitopes.  
Although there is evidence that all serotypes of A. pleuropneumoniae can cause severe 
disease and death in pigs, significant differences in virulence have been observed (Frey, 
1995; Rogers et al., 1990; Rosendal et al., 1985).  These variations may be partly attributed 
to the production of different combinations of Apx toxins, with the most virulent serotypes 
producing both Apx I and Apx II (Frey, 1995).  Field observations and experimental infections 
provide evidence that biotype 2 strains are less virulent than biotype 1 strains.  Field 
observations also indicate that biotype 1 serotype 1a, 1b, 5a, 5b, 9 and 10 strains are more 
virulent than the other biotype 1 serotypes.  This was, however, not confirmed under 
experimental conditions (Dom and Haesebrouck, 1992a ; Jacobson et al., 1995). 
2. PREVALENCE AND EPIZOOTIOLOGY 
Pleuropneumonia is a major problem in much of Europe, the USA, Canada and Eastern Asia.  
Control measures may suppress clinical disease but reports from many countries suggest that 
30-50% of all pigs are infected.  In Belgium, the biotype 1-serotypes 2, 3, 5, 6, 7, 8,  9 and 11 
strains and the biotype 2-serotype 2 strains are mostly found (Hommez et al., 1988; Hommez 
et al., 1990).   
A. pleuropneumoniae can be isolated from nasal cavities, tonsils, middle ear cavities and 
lungs of infected pigs (Dom et al., 1994; Duff et al., 1996; Sidibe et al., 1993).  The bacterium 
is normally not considered as invasive, but there is one report of A. pleuropneumoniae being 
recovered from osteomyelitis in pigs (Jensen et al., 1999).  The bacterium is mainly 
transmitted by direct contact between infected pigs or by aerosols.  After clinical or subclinical 
infections, pigs can become carriers of A. pleuropneumoniae.  In such pigs, the infectious 
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agent is located mainly in necrotic lung lesions and/or tonsils, less frequently in the nasal 
cavities (Nicolet, 1992; Sidibé et al., 1993).   
Transmission between herds occurs through the introduction of carriers to populations without 
previous experience of the disease. A. pleuropneumoniae is a strict pathogen of the porcine 
respiratory system, has a very short survival time in the environment and is very fragile and 
sensitive to the usual disinfectants (Taylor, 1999).  The bacterium can survive for a few days 
in mucus or other organic material (Nicolet, 1992).  In case of acute outbreaks of 
pleuropneumonia, indirect transmission can occur via exudate on booths or clothing (Nicolet, 
1992).   
An increased incidence of pleuropneumonia is associated with stress situations such as 
transports, stable changing, overcrowding and inappropiate housing (Nicolet, 1992).  Another 
trigger factor is infection with other respiratory pathogens.  It was demonstrated that a 
concomitant infection with Mycoplasma hyopneumoniae (Caruso and Ross, 1990; Yagihashi 
et al., 1984) or with Aujeszky’s disease virus (Sakano et al., 1993) can worsen the symptoms 
of pleuropneumonia.  In contrast, a concomitant experimental infection with PRRSV had no 
effect on clinical symptoms and lesions caused by A. pleuropneumoniae (Pol et al., 1997).  
Sows from a chronically infected herd confer passive immunity to their offspring through 
colostral antibodies (Nielsen, 1985).  As the colostral antibody level declines, the piglets 
become susceptible to infection.  Where the infection is enzootic, the condition is mostly 
found amongst pigs of 6-12 weeks of age. 
3. CLINICAL SIGNS AND LESIONS 
The pace of disease can range from peracute to chronic depending on the serotype, the 
immune status of the host, and the infection doses (Cruijsen et al., 1995; Hensel et al., 1993; 
Rogers et al., 1990; Rosendal et al., 1985; Sebunya et al., 1983).  Peracutely or acutely 
diseased pigs may have some or all of the following clinical symptoms: high fever, increased 
respiratory rate, coughing, sneezing, dyspnoea, anorexia, ataxia, vomiting, diarrhoea and 
severe respiratory distress with cyanosis and presence of haemorrhagic foam on mouth 
and/or nostrils (Ajito et al., 1996; Ligget et al., 1987; Rosendal et al., 1985; Taylor, 1999).  
The subacute and chronic forms develop after the disappearance of acute signs.  Recovering 
animals may cough, and show respiratory distress particularly when disturbed.  Exercise 
intolerance may continue for days and affected animals may have reduced appetite, appear 
gaunt and hairy, be depressed and show reduced rates of liveweight gain.   
Lesions are mainly characterised by a hemorrhagic necrotizing pneumonia and fibrinous 
pleuritis (Figure 1).  The pneumonia is mostly bilateral, with involvement of the cardiac and 
apical lobes, as well as at least part of the diaphragmatic lobes where pneumonic lesions are 
often focal and well demarcated. In the peracute and acute form of the disease, pulmonary 
lesions are characterised by severe oedema, inflammation, haemorrhage and necrosis (Ajito 
et al., 1996; Bertram et al., 1985; Rosendal et al., 1985).  The thoracic cavity is often filled 
with bloody fluid and fibrin clots.  Diffuse fibrinous pleuritis and pericarditis are also common 
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(Rosendal et al, 1985).  Tracheobronchial and mesenteric lymph nodes can have oedema 
and become swollen as a result of neutrophil infiltration and fibrin deposition (Ajito et al., 
1996; Ligget et al., 1987; Rosendal et al., 1985).  Animals that survive infection may have 
complete resolution of lesions, but frequently they retain necrotic foci, encapsulated 
abscesses and/or adhesive pleuritis (Ligget et al., 1987; Rosendal et al., 1985) (Figure 2).   
Histologically, in the early stages of disease, polymorphonuclear leukocyte (PMN) infiltration, 
oedema and fibrinous exudate are present (Ajito et al., 1996; Bertram et al., 1985; Ligget et 
al., 1987).  In the later stages, macrophage infiltration is more apparent and necrotic areas 
are surrounded with dense bands of degenerating leukocytes (Ajito et al., 1996; Bertram et 
al., 1985; Ligget et al., 1987).  Within alveoli, degeneration of pulmonary epithelial cells, 
macrophages and PMNs is seen (Ajito et al., 1996; Perfumo et al., 1983).  Severe necrotising 
vasculitis leads to a disrupted blood-lung barrier resulting in haemorrhage (Ligget et al., 1987; 
Rosendal et al., 1985; Serebrin et al., 1991).  Degenerating erythrocytes, fibrin and platelet 
thrombi are found within dilated capillaries in the lung (Perfumo et al., 1983). 
The bacteria can be found within the alveolar and interlobular fluid and they may spread via 
lymph vessels from the parenchyma to the pleura, but bacteraemia is rare (Ajito et al., 1996).  
Large numbers of bacteria are phagocytosed by macrophages and PMNs.  The bacterium 
does not invade epithelial cells (Min et al., 1998).  
        
    
 
Figure 1.  Hemorrhagic necrotizing pneumonia (left) and fibrinous pleuritis (right) in acute A. 
pleuropneumoniae infections 
       
Figure 2.  Abscess (left) and adhesive pleuritis (right) in chronic A. pleuropneumoniae 
infections 
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4. PATHOGENESIS 
The pathogenesis of porcine pleuropneumonia is considered to be multifactorial (Nicolet, 
1992).  There are three basic stages in the pathogenesis: colonisation, evasion of host 
clearance mechanisms, and damage to host tissues.   
Colonisation 
Colonisation, the ability of a pathogen to adhere to host cells or surfaces and to multiply within 
the host, is generally regarded as an important prerequisite for virulence manifestation of 
bacteria (Ofek and Beachy, 1980).  It was demonstrated that A. pleuropneumoniae does not 
bind well to the cilia or epithelium of the trachea or bronchi but does bind intimately with the 
cilia of terminal bronchioli and epithelial cells of the alveoli (Dom et al., 1994).  Thus, while A. 
pleuropneumoniae can be isolated from the tonsils and nasal cavities of pigs (Chiers et al., 
1999; Sidibe et al., 1993) it is not yet clear if colonisation of the upper respiratory tract is 
necessary for pulmonary infection in naturally occurring cases of pleuropneumonia.  This may 
depend on the nature of the infectious material encountered by the animal (aerosol or mucus 
secretions).  Aerosol particles are small enough to penetrate into the lower respiratory tract, 
obviating the need for colonisation of the upper respiratory tract (Kaltrieder et al., 1976). 
Evasion of host clearance mechanisms 
Rapid clearance of bacteria from the respiratory tract is an effective host defence against 
bacterial infections in the lung.  A number of defence mechanisms clear or destroy any 
bacteria inhaled with air or fortuitously deposited in the airway passages.  Nasal clearance is 
the removal of particles, including aerosols carrying micro-organisms that are deposited near 
the front of the airway.  Those deposited on the nonciliated epithelium are normally removed 
by sneezing or blowing, whereas those deposited posteriorly are swept over the mucus-lined 
ciliated epithelium to the nasopharynx, where they are swallowed.  Tracheobronchial 
clearance is accomplished by mucociliary action: the beating motion of cilia moves mucus 
continuously from the lung toward the oropharynx.  Particles deposited on this film are 
eventually either swallowed or expectorated.  In the alveoli, bacteria can be eliminated by the 
action of phagocytic cells.  In healthy animals, macrophages are the predominant phagocyte 
found in the lower respiratory tract, whereas the number of PMNs is generally small, but 
increases rapidly following infection (Bertram et al., 1985; Sibille et al., 1990).  Alveolar 
macrophages (AMs) are strategically situated at the air-surface interface in the alveoli, and 
are thus the first cells to encounter inhaled organisms.  Both macrophages and PMNs 
phagocytose A. pleuropneumoniae.  Following phagocytosis, PMNs can effectively kill A. 
pleuropneumoniae whereas macrophages cannot (Cruijsen et al., 1992).  This is probably 
due to the more potent bactericidal capacity of PMNs (Cruijsen et al., 1992; Sibille et al., 
1990).  A. pleuropneumoniae may survive for more than 90 minutes within macrophages, 
during which time liberation of Apx toxins may result in lysis of these phagocytes (Cruijsen et 
al., 1992).  These Apx toxins are the major factors involved in the impairment of phagocytic 
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function of macrophages and PMNs.  Furthermore, A. pleuropneumoniae produces several 
factors which may contribute to its ability to survive within the macrophages: capsule and 
lipopolysaccharides (Bilinski et al., 1991); copper-zinc superoxide dismutase (Langford et al., 
1996); stress proteins (Fuller et al., 2000); and ammonia (Bossé et al., 2000). 
Damage to host tissues 
Most of the pathological consequences of pleuropneumonia can be attributed to the Apx 
toxins which exert cytotoxic effects on endothelial cells (Serebrin et al., 1991), macrophages 
(Dom et al., 1992b), neutrophils (Dom et al., 1992a) and alveolar epithelial cells (Van de 
Kerkhof et al., 1996).  Activation of neutrophils, alveolar and intravasal macrophages, largely 
due to Apx toxins and LPS, leads to release of toxic oxygen metabolites, as well as proteolytic 
enzymes and various cytokines (Dom et al, 1992a; Dom et al., 1992b; Sibille et al., 1990; 
Pabst, 1996; Udeze et al., 1987).  LPS can enhance the effects of Apx toxins on phagocytes 
(Fenwick, 1994).   
5. ROLE OF VIRULENCE FACTORS IN PATHOGENESIS 
AND PROTECTION 
Different virulence factors have been described, including capsules, lipopolysaccharides, 
outer membrane proteins, transferrin binding proteins, proteases, Apx toxins and adhesins 
(Figure 3).   
 
 
 
Figure 3. Virulence factors of A. pleuropneumoniae. 
Capsule 
Capsules are found in all strains of A. pleuropneumoniae.  They mainly consist of derivatized 
repeating oligosaccharides that determine serotype specificity (Beybon et al., 1993; Perry et 
al., 1990).  The capsule is responsible for the characteristic iridescence of the colony on a 
clear medium.   
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The chemical composition and structure of the capsule for the serotypes 1-12 have been 
determined (Perry et al., 1990).  In general, these consist of repeating oligosaccharide units 
(serotypes 5a, 5b and 10), techoic acid polymers joined by phosphate diester bonds 
(serotypes 2, 3, 6, 7, 8, 9 and 11) or oligosaccharide polymers joined through phosphate 
bonds (serotypes 1, 4 and 12) (Perry et al., 1990).   
The DNA region involved in export of the capsular polysaccharide of A. pleuropneumoniae 
serotype 5a has been identified and characterized (Ward and Inzana, 1996). 
Variation in virulence can be attributed, at least in part, to the composition and structure of the 
capsule or the amount of capsular polysaccharides on the cell.  Using electron microscopy, a 
direct correlation between the virulence of the strain and the thickness of the capsule was 
demonstrated (Jensen and Bertram, 1986).   
Although purified A. pleuropneumoniae capsular polysaccharides do not induce clinical illness 
or lesions in pigs (Fenwick et al., 1986), the capsule is essential for A. pleuropneumoniae 
virulence in vivo (Tascon et al., 1996), probably as a virulence factor that allows the bacterium 
to resist the antibacterial environment produced by the host’s immune system.  The capsular 
polysaccharides protect A. pleuropneumoniae against phagocytosis and lysis by complement 
(Inzana et al., 1988).   
Antibodies directed against the capsule opsonize the bacterium and may play a role in 
serotype specific partial protection induced by vaccination with bacterins.  Inzana et al. (1991, 
1993) showed that a non-encapsulated Apx toxin producing mutant gave good protective 
immunity against A. pleuropneumoniae challenge while a non-toxin producing but capsulated 
mutant gave virtually no protection.  This demonstrates that Apx toxins are more important in 
protection than capsule.   
Lipopolysaccharides 
Lipopolysaccharides (LPS) are essential structural components of the outer membrane of 
Gram-negative bacteria.  They consist of a polysaccharide and a lipid A moiety, of which the 
latter is a toxic compound (endotoxin).  The polysaccharide moiety consists of a core and O 
side chains.  This typical complete structure is referred to as the smooth (or S-form) 
chemotype.  Strains which have lost the O-polysaccharides are referred to as the rough (or R-
form) chemotype.  An intermediate form (with one or a limited number of O-side chains), 
called semi-rough, also exists in A. pleuropneumoniae. 
Even though a capsule is present at the surface of this bacterium, studies have revealed that 
LPS can traverse the thick capsular material and reach the outmost region of the cell (Paradis 
et al., 1996). 
Although many of the pathological consequences of A. pleuropneumoniae infection have 
been attributed to LPS, extremely large doses of purified LPS are required to induce lesions 
similar to those found in naturally infected pigs (Fenwick et al., 1986; Udeze et al., 1987).  
Furthermore, pigs infected with a mutant of a serotype 1 strain lacking Apx toxins, but with 
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normal LPS, do not develop clinical disease or lung lesions (Tascon et al., 1994). This 
indicates that LPS is not responsible for the typical A. pleuropneumoniae lesions.   
LPS activate the alternative complement cascade resulting in release of complement 
components that attract and activate PMNs and macrophages and stimulate release of 
inflammatory mediators, resulting in further PMN and platelet activation, vasodilation and 
constriction of pulmonary airways (Bertram, 1988; Udeze et al., 1987).   
LPS have also been implicated in adhesion of A. pleuropneumoniae to tracheal mucus, 
tracheal and lung frozen sections (Paradis et al, 1994) and host glycosphingolipids (Abul-Mihl 
et al., 1999).   
Pigs immunised with LPS were only partially protected against challenge with the homologous 
A. pleuropneumoniae serotype (Inzana, 1988), indicating that  LPS may play a role in the 
partial serotype specific protection that is induced by vaccination with bacterins.   
Outer membrane proteins 
Several proteins of the outer membrane of A. pleuropneumoniae are recognized by 
convalescent sera.  Furthermore, specific outer membrane proteins can be induced under 
conditions of iron restriction or addition of maltose (Deneer and Potter, 1989a&b; Jansen, 
1994).  Although outer membrane protein profiles differ for most serotypes of A. 
pleuropneumoniae (Rapp et al, 1986), it has been shown that isolates of all serotypes contain 
several common outer membrane proteins, including the peptidoglycan-associated lipoprotein 
PalA of 14 kDa (Frey et al., 1996), a 29/41-kDa heat-modifiable protein, a major protein that 
varies from 32 to 42 kDa depending on the serotype and a 48-kDa protein (Cruz et al., 1996).  
DNA sequence analysis of the gene encoding PalA revealed high similarity of the protein's 
amino acid sequence to that of the E. coli peptidoglycan-associated lipoprotein PAL, to the 
Haemophilus influenzae  outer membrane protein P6 and to related proteins of several Gram-
negative bacteria.  This gene is conserved and expressed in all A. pleuropneumoniae 
serotypes and in A. lignieresii.  A very similar gene is present in A. suis and A. equuli (Frey et 
al., 1996). 
PalA as well as proteins of 32K and 42K are immunodominant (Frey et al., 1996; Jansen, 
1994; MacInnes and Rosendal, 1987).  Immunisation with an outer membrane extract or a 
crude outer membrane preparation conferred limited protection against challenge with A. 
pleuropneumoniae (Beaudet et al, 1994; Jansen, 1994).  Immunisation with recombinant 
outer membrane lipoprotein Oml A (40 kDa), which is probably present in all serotypes of A. 
pleuropneumoniae, protected pigs from death upon challenge with the homologous strain, but 
lesions were found in the lungs and A. pleuropneumoniae  was isolated from the lungs 
(Gerlach et al, 1993).  This indicates that antibodies against Oml A may contribute to, but are 
not sufficient for protection of pigs against A. pleuropneumoniae  infection (Jansen, 1994). 
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Transferrin binding proteins 
Iron is essential for bacterial growth.  However, it is not readily available in the extracellular 
environment of the host due to complexation by the host glycoproteins, transferrin and 
lactoferrin.  A. pleuropneumoniae expresses a number of factors that are involved in the 
acquisition and uptake of iron.  It is capable of utilising porcine transferrin, but not transferrin 
from other animal species, as a sole source of iron (Niven et al., 1989).  These receptors are 
expressed under iron limited conditions.  They consist of two distinct proteins.  Transferrin 
binding protein A (also known as Tbp1) has an approximate molecular mass of 100 kDa and 
likely forms a transmembrane channel for transport of iron across the outer membrane 
(Gonzalez et al., 1995; Wilke et al., 1997).  The transferrin binding protein B (also known as 
Tbp2) has an approximate molecular mass of 60 kDa and appears to be a lipoprotein 
anchored to the outer membrane by N-terminal fatty acid residues (Fuller et al., 1998; Gerlach 
et al., 1992; Gonzalez et al., 1995).  The pathway of iron acquisition suggested by Kirby et al. 
(1995) involves binding and iron removal from transferrin at the bacterial surface by the co-
ordinate action of TbpA and TbpB followed by transport of iron across the outer membrane 
via Tbp A and binding of iron by a periplasmic binding protein.   
Although both proteins are surface accessible and bind to the C-lobe of porcine transferrin, 
there is evidence that an interaction between these proteins is required for optimal utilisation 
of transferrin as a source of iron (Fuller et al., 1998; Gonzalez et al., 1995; Litt et al., 2000).   
In addition, Gerlach et al. (1992) showed that TbpB is also capable to bind haemin but not 
haemoglobin.  This binding specificity has not been tested for TbpA.   
Immunisation of pigs with the TbpB conferred limited protection against challenge with the 
homologous strains (Gerlach et al., 1992 ; Rossi-Campos et al., 1992).  This indicates that 
Tbp proteins contribute to, but are not sufficient for protection of pigs against A. 
pleuropneumoniae  infection (Jansen, 1994). 
A. pleuropneumoniae can also use haem compounds including free haem, haemin, haematin 
and haemoglobin as a source of iron (Deneer and Potter, 1989).  All serotypes of A. 
pleuropneumoniae are capable of obtaining haem products via production of haemolysins 
(Frey et al., 1993).   
Proteases 
 All serotypes of A. pleuropneumoniae appear to secrete a high-molecular-mass protease 
complex (>200 kDa) that degrades porcine gelatine, Ig A and haemoglobin (Garcia-Cuellar et 
al., 2000; Negrete-Abascal et al., 1994).   It has been suggested that the Ig A cleaving 
proteases could facilitate the mucosal spread of A. pleuropneumoniae  and that proteolytic 
cleavage of haemoglobin could be a mechanism of iron acquisition.  The exact role of these 
proteases in the development of pathology has yet to be investigated. 
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Apx toxins 
Four Apx toxins have been described: two hemolytic exotoxins (ApxI and Apx II), one non-
hemolytic exotoxin (ApxIII) and one exotoxin that is only produced in vivo (ApxIV) (Dom et al., 
1994a ; Frey et al., 1993 ; Frey et al., 1994 ; Jansen, 1994; Kamp et al., 1991 ; Schaller et al., 
1999).  They are toxic for porcine alveolar macrophages and neutrophils and belong to the 
family of pore forming RTX-toxins, a group of protein toxins which is widely spread among 
pathogenic Gram-negative bacteria (Frey et al, 1994).  
ApxI is a strongly hemolytic and cytolytic protein with an apparent molecular mass of 105 
kDa.  It was previously named haemolysin I or cytolysin I and shows strong similarities to the 
Escherichia coli α-haemolysin and to a lesser extent to the Mannheimia haemolytica 
leukotoxin.  It is produced by serotypes 1, 5, 9, 10 and 11 as well as by Actinobacillus suis  
(Kamp et al., 1994). 
ApxII is a weakly hemolytic and weakly cytotoxic exotoxin which was previously named 
haemolysin II or cytolysin II.  It has an apparent molecular mass of 103 kDa and is produced 
by all serotypes, except serotype 10.  It is also produced by Actinobacillus suis (Kamp et al., 
1994).  Based on DNA derived amino acid sequence ApxII is closely related to the 
Mannheimia haemolytica  leukotoxin. 
ApxIII is not hemolytic but strongly cytotoxic.  It was previously named pleurotoxin.  It is 
produced by biotype1 serotype 2, 3, 4, 6 and 8 strains and has an apparent molecular mass 
of 120 kDa.   
In contrast to ApxI, ApxII and ApxIII cytotoxins, each of which is produced by some but not all 
serotypes, the ApxIV toxin is produced by all serotypes (Cho and Chae, 2001; Schaller et al., 
1999).  The apxIV gene product could not be detected in A. pleuropneumoniae cultures grown 
under various conditions in vitro.  Pigs experimentally infected with serotypes 1, 5 or 7 
produced antibodies that reacted with the ApxIV toxin (Schaller et al., 1999), suggesting that 
the apxIV gene product is induced in vivo.  The apxIV gene was detected in degenerating 
neutrophils and macrophages by Cho and Chae (2001).  This suggests that ApxIV toxin may 
lead to host-mediated tissue damage by the lysis of inflammatory cells.  Further studies on 
function and regulation of the apxIV gene in vivo are needed.  
The structural toxin genes as well as the genes encoding activation and secretion of the Apx 
toxins have been characterised (for a review, see Frey et al., 1994; Frey, 1995; Jansen, 
1994). 
It is now clear that Apx toxins play an important role in the pathogenesis of porcine 
pleuropneumonia.  They play a role in evasion of the hosts first line defence: at high 
concentrations RTX toxins form pores in membranes of phagocytic and other target cells, 
resulting in osmotic swelling and cell death.  Most of the pathological consequences of 
porcine pleuropneumonia can be attributed to the Apx I, II and III toxins: they are toxic for 
endothelial cells (Serebrin et al., 1991) and provoke an oxidative burst in macrophages (Dom 
et al., 1992c) and neutrophils (Dom et al., 1992b) resulting in excessive production of oxygen 
radicals which can have deleterious effects on host cells.  Moreover, purified recombinant Apx 
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toxins were able to cause lesions upon endobronchial instillation and mutant strains which are 
unable to produce Apx toxins did not induce lesions (Kamp et al., 1993; Stockhofe-Zurwieden 
et al., 1996). Use of transposon mutagenesis (Tascon et al., 1994) and complementation 
experiments (Reimer et al., 1995) also prove that Apx toxins are essential in the pathogenesis 
of porcine pleuropneumonia. 
It was demonstrated that A. pleuropneumoniae and its metabolites are able to kill type II 
alveolar epithelial cells and that cytotoxicity is at least in part due to production of Apx toxins 
(Van De Kerkhof et al., 1996).  It is remarkable that rabbit sera against ApxI and ApxII were 
not able to protect alveolar epithelial cells against the biotype 1 serotype 1 strain although 
such sera were able to neutralize toxicity of culture supernatant.  It has been shown that A. 
pleuropneumoniae adheres to alveolar epithelial cells in vivo (see below). It was 
demonstrated that this also occurs in vitro (Haesebrouck et al., 1996). This association may 
mediate delivery of high concentrations of Apx toxins directly to the surface of the alveolar 
epithelial cells, resulting in destruction of the target cells even in the presence of neutralizing 
antibodies. It has been described that toxins produced by adhering bacteria are targeted more 
efficiently and become relatively inaccessible to neutralization by toxin inhibitors (Ofek et al., 
1990). 
The importance of Apx toxins in protective immunity against porcine pleuropneumonia was 
demonstrated by immunisation with Apx toxins in combination with other bacterial 
compounds.  In these experiments the Apx toxins were essential vaccine components to 
confer protection against challenge (Beaudet et al., 1994 ; Byrd and Kadis, 1992 ; Frey, 1995; 
Van den Bosch et al., 1992 ; Jansen, 1994 ).  However, it has also become clear that the Apx 
toxins are not the only factors involved in protective immunity. 
Adhesins 
During the course of many infectious diseases, including pulmonary infections, bacteria 
colonize body sites by engaging their surface-bound adhesins with cognate receptors 
available on host cells.  The recognition and attachment processes are therefore considered 
to be the first steps in establishing bacteria at a given site. It is a prerequisite for colonization 
and virulence manifestation of bacteria (Ofek and Beachy, 1980).  Adherence enables 
colonization to occur and allows the bacterium to exert its pathogenic effects. 
It was shown that A. pleuropneumoniae adheres to the epithelium of the alveoli or the cilia of 
the terminal bronchioli of experimentally infected pigs (Dom et al., 1994).  It has also been 
shown that A. pleuropneumoniae adheres to porcine tracheal rings maintained in culture 
(Bélanger et al., 1990), to porcine frozen tracheal and lung sections (Jacques et al., 1991), to 
erythrocytes from various animal species (Jacques et al., 1988), to tonsillar epithelial cells 
(Chiers et al., 1999), to swine buccal epithelial cells (Hamer et al., 1999) and to type III swine-
lung collagen (Enriquez et al., 1999). 
Several surface structures have been described in the family of Pasteurellaceae that are 
involved in adhesion, including the capsule (Confer et al., 1995), fimbriae (Read et al., 1992), 
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lipopolysaccharides (Bélanger et al., 1990) and outer membrane proteins (Confer et al., 
1995).  Concerning A. pleuropneumoniae, only few adhesion factors have been described.  
Lipopolysaccharides seem to be involved in the in vitro adhesion to porcine tracheal rings 
(Bélanger et al., 1990) and mucus (Bélanger et al., 1992&1994).  It was shown that the 
capsule is not responsible for adherence to tracheal frozen sections (Jacques, 1999).  Type 4 
fimbriae have been demonstrated on A. pleuropneumoniae (Dom et al., 1994a; Utrera and 
Pijoan, 1991; Zhang et al. 2000) but their role in adherence needs to be elucidated.  
6. DISEASE CONTROL WITH EMPHASIS ON VACCINATION 
Disease control of pleuropneumonia may be accomplished in a number of different ways: (1) 
antimicrobial treatment, (2) vaccination, (3) isolation-treatment-vaccination combination, and 
(4) eradication.  Besides these measures, control of environmental factors such as 
temperature and ventilation and use of solid partitions between pens is essential.  
Desinfection should be included in any control program; the organism is sensitive to a wide 
range of commonly used desinfectants (Gutierrez et al., 1995). 
Antimicrobial treatment 
Antimicrobial therapy is efficient only in the initial phase of the disease, when it can reduce 
mortality.  For treatment of acutely affected animals antimicrobials should be applied in high 
dosage and parenterally (subcutaneously or intramuscularly), as affected animals have 
reduced food and water consumption.  To ensure effective and durable blood concentrations, 
repeated injections may be required.  A combination of parenteral and peroral medication in a 
recent outbreak often gives best results. The success of therapy depends mainly on early 
detection of clinical signs and on rapid therapeutic intervention.  In some outbreaks, 
reapparance of the disease occurs a few weeks after cessation of peroral therapy.  In these 
cases, pulse medication is sometimes recommended i.e. medication periods (during 4 or 5 
days) interrupted by periods during which animals are not treated (during 4 or 5 days).  The 
idea behind pulse medication is that during the non-treatment period animals build up 
immunity.   
Both lung damage and fibrous pleurisy may persist affecting the performance for the 
remainder of the finishing period.  Lesions may be colonised by organisms such as 
Pasteurella spp. and these may persist after A. pleuropneumoniae has been eliminated.   
A. pleuropneumoniae is particularly susceptible in vitro to penicillin, amoxicillin, ampicillin, 
cephalosporin, tetracyclines, colistin, sulfonamide, combination of trimethoprim and 
sulfamethoxazole, and gentamicin.  Higher minimum inhibitory concentrations (MIC) values 
are found for streptomycin, kanamycin, spectinomycin, spiramycin and lincomycin (Nicolet 
and Schifferli, 1982; Gilbride and Rosendal, 1984; Nadeau et al., 1988; Inoue et al., 1984; 
Hommez et al., 1988).  Gilbride and Rosendal (1984) and Vaillancourt et al. (1988) described 
that acquired resistance to ampicillin, streptomycin, sulfonamides and tetracyclines is frequent 
in serotypes 1, 3, 5 and 7 but rare in other serotypes, particularly serotype 2 (Nicolet and 
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Schifferli, 1982; Inoue et al., 1984).   Acquired resistance to oxytetracycline has also been 
described by Dom et al. (1994a) in Belgian A. pleuropneumoniae strains belonging to 
serotypes 2, 3, 5b, 8 and 9.  Antibiotic resistance is generally speaking plasmid mediated 
(Hirsh et al., 1982; Huether et al., 1987; Wilson et al., 1989).   
The betalactams (penicillins and cephalosporins), trimethoprim and sulfamethoxazole, and 
tetracyclines are considered to be most active.  Quinolone derivates (enrofloxacin) (Kobisch 
et al., 1990) or the semi-synthetic cephalosporin ceftiofur sodium (Stephano et al., 1990) have 
been shown to be particularly effective after experimental challenge.  Tiamulin and a 
combination of lincomycin and spectinomycin also gave satisfactory results in the field.  
Tilmicosin has been used in feed by Moore et al. (1996).  Antimicrobial sensitivity testing is 
recommended where problems are being experienced with treatment. 
An important disadvantage of antimicrobial use is that it favours spread of resistance not only 
in pathogenic bacteria but also in bacteria belonging to the normal flora.  The latter can act as 
a reservoir for resistance genes.  Moreover, penetration of antimicrobials in necrotic lesions 
often is not sufficient to eliminate the bacterium, resulting in persistence of A. 
pleuropneumoniae in these lesions. 
Vaccination 
Bacterins 
Bacterins are inactivated whole-cell vaccines.  They consist of bacterial cell suspensions 
adjusted to an opacity of some 1010 organisms per ml, usually inactivated by treatment with 
formaldehyde, UV-light, ozone or heat.   
Vaccination with killed bacteria is serotype specific (Nielsen, 1984; Hensel et al., 1995a; 
Hensel et al., 1995b; Tarasiuk et al., 1994), but cross-immunity is possible with cross-reacting 
serotypes (Nielsen, 1985).  Furthermore, Jolie et al. (1995) demonstrated that protection 
induced by bacterins is not only serotype specific but even can be subtype specific.  The 
protection afforded can be extended by including all the serotypes present in a given 
geographic area.   
Bacterins prepared with a 6 hour culture gave significant better results than bacterins 
prepared with a 24 hour culture (Nielsen, 1976).  Data presented by Tarasiuk et al. (1994) 
indicate that there are no differences in efficacy between intramuscular and subcutanuous 
routes of vaccine administration.   
A bacterin contains capsular polysaccharides and lipopolysaccharides (Furesz et al., 1997).  
Formaldehyde inactivation may alter certain antigens by denaturation.  As a result, antibodies 
against these altered antigens may not recognize the original antigens.  This could explain the 
limited, serotype specific protection of many bacterins in the field (Fedorka-Cray et al., 1990; 
Higgins et al., 1985; Nielsen, 1976).   
The type of adjuvant used may affect efficacy.  Bacterins containing an oil-adjuvant are 
superior in stimulating antibody production and protection.  However, these vaccines are 
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frequently associated with tissue necrosis and abscess formation at the site of injection 
(Henry, 1983; Edelman, 1980; Straw et al.,1984).    
A single oral administration of inactivated A. pleuropneumoniae provided partial clinical 
protection against a homologous challenge infection (Hensel et al., 1995b).  Pigs exposed to 
vaccine aerosols of inactivated A. pleuropneumoniae biotype 1-serotype 2 or 9 had no clinical 
symptoms of pleuropneumonia or lung lesions when challenged with a serotype 9 strain 
(Hensel et al., 1996). 
Subunit vaccines 
Subunit vaccines are currently under development or being marketed and consist of varying 
combinations of subunits.  A wide range of antigens has been found to be protective.   
Immunisation of mice with a lipopolysaccharide containing vaccine resulted in partial 
protection against a homologous challenge with A. pleuropneumoniae.  To increase the 
immune response to the polysaccharides, high molecular mass O-polysaccharides were 
chemically coupled to the large immunogenic protein bovine serum albumine (Rioux et al., 
1997).  
Bak et al. (1990) investigated the immunogenicity and the toxic effect of a vaccine containing 
purified capsular polysaccharides and a trace of lipopolysaccharides.  Pigs immunized with 
this vaccine developed low antibody titers against these antigens.  Instillation of large 
amounts of capsular material in pigs resulted in pulmonary oedema, hemorrhage and 
degenerative changes of alveolar epithelial cells. 
It was demonstrated by Chiang et al. (1990) that vaccination of pigs with proteinase K-treated 
outer membrane fraction from A. pleuropneumoniae conferred better protection compared to 
vaccination with an untreated outer membrane fraction.   Although pigs vaccinated with the 
proteinase K-treated outer membrane fraction vaccine had higher antibody levels against the 
outer membrane proteins no direct correlation was found between specific antibody levels 
and protection. 
Neutralisation of the Apx toxins produced by A. pleuropneumoniae is very important in 
providing protection against pleuropneumonia.  A vaccine containing a mixture of ApxI and 
ApxII induced partial protection against an A. pleuropneumoniae serotype 1 strain (Haga et 
al., 1997).  Devenisch et al. (1990) and Cruijsen et al. (1995) found a correlation between the 
amount of Apx-neutralizing antibodies and protection.   
A vaccine containing a mixture of antigens can be used to induce better protection.  Madsen 
et al. (1995) compared the effects of vaccination with outer membrane proteins, ApxI toxin or 
a combination of outer membrane proteins and ApxI toxin.  It was concluded that (1) outer 
membrane proteins or Apx I toxin used individually induce incomplete protection; (2) outer 
membrane proteins plus Apx I toxin protect lung tissue better than when either virulence 
factor is used alone; (3) using outer membrane proteins plus ApxI toxin reduces the damage 
to lung tissue.  Immunization with subunit conjugate vaccines (i.e. capsular polysaccharides 
conjugated to the AxpI toxin or lipopolysaccharides conjugated to the ApxI toxin) resulted in 
  Introduction 
 24
antibody responses against each component of each conjugate (Byrd and Kadis, 1992).  Pigs 
immunized with a trivalent vaccine containing ApxI toxin, ApxII toxin and a 42 kDa outer 
membrane protein were partially protected against challenge with different A. 
pleuropneumoniae serotypes (Van den  Bosch et al., 1994). 
Recombinant expressed ApxII and transferrin binding protein A of an A. pleuropneumoniae 
serotype 7 strain induced better protection against challenge with an A. pleuropneumoniae 
serotype 7 strain than when bacterins were used (Rossi-Campos et al., 1992). 
Vaccination with a cell-free concentrate containing carbohydrates, endotoxin and protein with 
hemolytic and cytotoxic activity provided protection from mortality and significantly reduced 
morbidity to homologous challenge (Fedorka-Cray et al., 1993). 
Live vaccines  
Several studies were performed with live attenuated vaccines against A. pleuropneumoniae.  
Naturally occuring mutants or strains attenuated in the laboratory were used. 
Strain BES is an naturally occuring low virulence strain of A. pleuropneumoniae serotype 1.  
No reversion to virulence has been observed after successive passages in live pigs. 
Intranasal vaccination of pigs with this strain resulted in an overall decrease of mortality and 
lung lesions (Utrera et al., 1990). 
Inzana et al. (1993) treated A. pleuropneumoniae serotypes 1 and 5 with ethyl 
methanesulfonic acid.  This resulted in live, attenuated, stable strains without any detectable 
capsule.  These vaccines appeared to provide protection similar to that induced by the parent  
strain against homologous and heterologous serotype challenge.  
Byrd and Hooke (1997) evaluated temperature-sensitive mutants of A. pleuropneumoniae in 
mice.  Intranasal immunization with these mutants resulted in protection against challenge 
with the homologous wild-type strain. 
Isolation-treatment-vaccination combination 
Isolation using all-in, all-out systems within a farm reduces infection but does not prevent it.  
The use of vaccination or treatment prior to or at the move increases the degree of control 
(Taylor, 1999). 
Eradication 
Hysterectomy-derived herds are free of A. pleuropneumoniae infection and may be 
maintained free by isolation.  They form a source of disease-free stock for repopulation.   
Depopulation of farms, cleaning, desinfection and repopulation with disease-free animals can 
be carried out (Taylor, 1999).  Farms free from the disease and infection should maintain a 
policy of isolation coupled with the use of semen or embryos to introduce new genes.  Any 
animals introduced should be hysterectomy derived or originate from herds known to be free 
from the disease and from infection.  It may be appropriate to hold them in quarantine prior to 
introduction to the herds (Taylor, 1999). 
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Antimicrobial treatment alone has not been successful in eradication but combinations with 
vaccination, partial depopulation and removal of serological and tonsillar carriers has been 
successful (Taylor, 1999). 
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SCIENTIFIC AIMS 
 
A. pleuropneumoniae causes severe losses in the pig rearing industry.  Although the disease 
can be controlled by antimicrobial agents, the use of these products has several 
disadvantages including induction of acquired resistance in pathogenic bacteria and bacteria 
belonging to the normal flora of pigs.  Therefore, prevention should be encouraged in the 
control of the disease.  Vaccines could be very useful to control porcine pleuropneumonia.  
Rational design of effective antibacterial vaccines requires knowledge of the virulence factors 
of the bacterium and the pathogenesis of the disease.   
 
It has been shown that Apx toxins play an important role in the pathogenesis of porcine 
pleuropneumonia.  The first aim of this thesis was, therefore, to evaluate the efficacy of 
vaccines mainly based on the inclusion of these toxins.   
 
Inclusion of bacterial adhesins in subunit vaccines might be of value. Indeed, A. 
pleuropneumoniae first adheres to alveolar epithelial cells before it causes lung lesions. The 
hypothesis was that, once the bacteria have attached to their target cells, i.e. alveolar 
epithelial cells, the Apx toxins are released directly onto the host cell. Hereby, neutralizing 
antibodies have no opportunity to bind to the toxins and prevent their action.  Therefore, in the 
second part of this thesis, the purpose was to characterize the adhesion of A. 
pleuropneumoniae to alveolar epithelial cells in vitro and in vivo. 
 
In a final study it was determined whether pigs vaccinated with a bacterin consisting of 
bacteria grown under conditions resulting in high in vitro adhesion, were better protected 
against an A. pleuropneumoniae infection than pigs vaccinated with a bacterin consisting of 
bacteria grown under conditions resulting in low in vitro adhesion.  
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EXPERIMENTAL STUDIES 
CHAPTER 1.  EVALUATION OF THE EFFICACY OF 
COMMERCIALLY AVAILABLE VACCINES AGAINST 
PLEUROPNEUMONIA 
 
Effects of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 9 
of pigs vaccinated with inactivated vaccines containing the Apx toxins 
Effect of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 9 of 
pigs vaccinated with a vaccine containing Apx toxins and transferrin-binding proteins 
 
CHAPTER 2.  ADHESION OF ACTINOBACILLUS 
PLEUROPNEUMONIAE TO PORCINE ALVEOLAR EPITHELIAL 
CELLS IN VITRO AND IN VIVO 
 
Characterization of the in vitro adhesion of Actinobacillus pleuropneumoniae to 
alveolar epithelial cells 
Effect of culture conditions of Actinobacillus pleuropneumoniae serotype 2 and 9 
strains on in vivo adhesion to alveoli of pigs 
 
CHAPTER 3.  EVALUATION OF THE EFFICACY OF A 
VACCINE CONTAINING CANDIDATE-ADHESINS 
 
Effect of endobronchial challenge with Actinobacillus pleuropneumoniae serotype 10 
of pigs vaccinated with bacterins consisting of Actinobacillus pleuropneumoniae 
serotype 10 grown under NAD-rich and NAD-restricted conditions   
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SUMMARY 
The efficacy of two inactivated vaccines containing the Apx toxins of Actinobacillus 
pleuropneumoniae (Hemopig™, Biokema, Lausanne, Switzerland and Porcilis™ App, 
Intervet, Boxmeer, The Netherlands) was determined.  Ten pigs were vaccinated twice with 
Hemopig™ and eight pigs with Porcilis™ App.  Ten control animals were injected twice with a 
saline solution.  Three weeks after the second vaccination, all pigs were endobronchially 
inoculated with 10
5
 colony-forming units (CFU) of an A. pleuropneumoniae serotype 9 strain.  
Increased respiratory rate and/or fever were observed in all vaccinated and control pigs after 
challenge.  One pig of the Hemopig™ group and of the Porcilis™ App group died, whereas all 
pigs of the control group survived the challenge.  Surviving pigs were killed at 7 days after 
challenge.  The mean percentage of affected lung tissue was 34% in the control group, 16% 
in the Hemopig™ group, and 17% in the Porcilis™ App group.  A. pleuropneumoniae was 
isolated from the lungs of all 10 control animals, from 7 of the 10 animals vaccinated with 
Hemopig™ and from 5 of the 8 animals vaccinated with Porcilis™ App.  The mean bacterial 
titres of the caudal lung lobes were 1.4x10
6
 CFU/g in the control group, 1.7x10
3
 CFU/g in the 
Hemopig™ group, and 4.8x10
3
 CFU/g in the Porcilis™ App group.  In both vaccinated groups 
the mean number of days with dyspnoea, the mean number of days with fever, the mean 
percentage of affected lung tissue, and the mean bacterial titre in the caudal lung lobes were 
significantly lower than in the control group.  Significant differences between the two 
vaccinated groups were not observed.  It was concluded that both vaccines induced partial 
protection. 
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INTRODUCTION 
A. pleuropneumoniae is the causative agent of porcine pleuropneumonia which induces great 
economic losses in the pig-rearing industry.  It also causes severe animal suffering and 
hampers animal welfare.  Infected pigs may develop acute hæmorrhagic-necrotizing 
pneumonia and fibrinous pleuritis or chronic localized lung lesions and adhesive pleuritis 
(Nicolet, 1992).  For control of porcine pleuropneumonia, improvement of housing conditions 
and climate is essential.  To control outbreaks of this disease, vaccination may also be useful.  
Although whole-cell bacterins may reduce mortality after infection with the homologous 
serotype, they generally do not confer protection against challenge with heterologous 
serotypes (Fenwick and Henry, 1994).  An explanation for the limited protection might be the 
absence of secreted and certain bacteria-associated virulence factors in the bacterins.  More 
recently, vaccines containing the A. pleuropneumoniae-RTX-toxins (Apx toxins) have become 
commercially available.  Among the different serotypes of A. pleuropneumoniae, three of 
these exotoxins have been described and each serotype produces either one or two of them 
(Dom et al., 1994; Frey et al., 1993; Frey et al., 1994; Kamp et al., 1991).  Specific pathogen-
free (SPF) pigs vaccinated twice with a vaccine containing the Apx toxins and a 42-kDa outer 
membrane protein developed no or less severe clinical symptoms and lung lesions than non-
vaccinated controls after challenge with serotype 1, 2, and 9 strains (Kobisch and Van den 
Bosch, 1992; Van den Bosch et al., 1992).  Field trials carried out in France (Pommier et al., 
1996), the Netherlands (Valks et al., 1996), and Italy (Martelli et al., 1996) confirmed that 
vaccination with this vaccine can result in reduction of clinical symptoms and lung lesions of 
acute and chronic pleuropneumonia and improvement of production parameters (growth, feed 
conversion, medication). 
In the present study, the efficacy of two inactivated vaccines containing the Apx toxins of A. 
pleuropneumoniae was evaluated, using a well-standardized challenge model which results in 
the acute form of porcine pleuropneumonia (Dom and Haesebrouck, 1994; Haesebrouck et 
al., 1996). 
MATERIALS AND METHODS 
Challenge strain 
The A. pleuropneumoniae biotype 1-serotype 9 strain (reference nr 13261) was used (Smits 
et al., 1991).  Bacteria were grown for 6 hours (log phase of growth) on Columbia agar 
(Columbia Agar Base, Lab M, Bury, Great Britain) supplemented with 3% horse serum, 0.03% 
NAD (Sigma Chemical Co, St Louis, Mo, USA), and 5% yeast extract at 37°C in a humid 
atmosphere with 5% CO2.  Bacteria were harvested in phosphate-buffered saline solution 
(PBSS, pH 7.3), centrifuged at 400 x g for 20 minutes, and suspended in RPMI 1640 
supplemented with 10% non-essential amino acids, 10% glutamine, 10% fetal calf serum, and 
1% sodium pyruvate.  The suspension was checked for purity and the number of colony-
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forming units (CFU) was determined by plating tenfold dilutions on Columbia agar 
supplemented with 3% horse serum, 0.03% NAD, and 5% yeast extract.  Bacterial 
suspensions were stored overnight at 4°C.  The next day, they were used in the experiments. 
Pigs 
In these studies 28 pigs were used.  All animals were obtained by using a medicated 
segregated early weaning programme.  They were weaned at 18 days of age and kept in 
isolation until used in the experiments. 
Vaccines 
Two commercial subunit vaccines were used, Hemopig™ (Biokema S.A., Lausanne, 
Switzerland) and Porcilis™ App (Intervet, Boxmeer, The Netherlands).  The Hemopig™ 
vaccine contains the capsular antigens of an A. pleuropneumoniae serotype 2, 7, and 9 
strain, their Apx toxins, and the Apx toxins of a serotype 1 strain.  The Porcilis™ App vaccine 
contains Apx I, II, and III toxins and a 42-kDa outer membrane protein (Van den Bosch et al., 
1992). 
Experimental design 
At the age of 19 and 22 weeks, 10 pigs were injected subcutaneously with 4 ml of the 
Hemopig™ vaccine, 8 pigs were injected intramuscularly with 2 ml of the Porcilis™ App 
vaccine, and 10 pigs were injected subcutaneously with 4 ml of a saline solution.  Three 
weeks after the second vaccination, all pigs were experimentally infected.  The pigs were 
anaesthetized with azaperone 2 mg/kg IM (Stresnil®, Janssen Pharmaceutica, Beerse, 
Belgium) and thiopental 10 mg/kg IV (Pentothal®, Abott, Louvain-La-Neuve, Belgium).  They 
were inoculated endobronchially with 10
5
 CFU of the A. pleuropneumoniae serotype 9 strain 
in 5 ml inoculum (Dom et al., 1992; Haesebrouck et al., 1996).  All pigs were examined 
clinically.  Pigs that died were autopsied immediately; those that survived the challenge were 
killed 7 days after inoculation.  At necropsy, the lungs were examined macroscopically and 
the percentage of affected lung tissue was determined.  For this purpose, a diagram was 
used that divides the lung into 74 equal triangles (Hannan et al., 1982).  The percentage of 
affected lung tissue was determined by summation of the triangles showing pneumonia 
and/or pleuritis divided by 74.  Samples from lungs, tracheobronchial lymph nodes, tonsils, 
liver, kidney, and spleen were taken for bacteriological examination.  Sera were collected 
before the first and the second vaccination and before the challenge. 
Clinical examination 
The pigs were examined for signs of pneumonia, characterized by increased respiratory rate 
(>40 inspirations/min), dyspnoea, sneezing, coughing, and the presence of bloody foam on 
mouth and/or nostrils.  Rectal temperature was measured 1 day before inoculation, just 
before inoculation, and during the 7 days after inoculation.  Other indications of infection were 
vomiting and a depressed appearance. 
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Bacteriological examination 
Twenty per cent (w/v) suspensions of the right and the left caudal lung lobes were made in 
PBSS.  The number of CFU was determined by plating tenfold dilutions of the suspensions on 
Columbia agar supplemented with 3% equine serum, 0.03% NAD, and 5% yeast extract.  
Samples were also grown on Columbia agar supplemented with 5% bovine blood with a 
Staphylococcus intermedius streak.  Twenty per cent (w/v) suspensions of tonsils were made 
in PBSS and inoculated onto blood agar with S. intermedius.  Suspected colonies were 
subcultured on the same medium.  Samples from lung lesions, tracheobronchial lymph nodes, 
liver, kidney, and spleen were tested for the presence of A. pleuropneumoniae by making an 
incision in these tissues and taking a sample with an inoculation loop.  These samples were 
also inoculated onto blood agar with S. intermedius. 
Serology 
All pig sera were tested for neutralizing antibodies against Apx I, Apx II, and Apx III, using a 
bioassay based on neutral red uptake by viable pulmonary alveolar macrophages, as 
described previously (Dom et al., 1994). 
Statistical analysis 
Statistical analysis was performed on the following variables: mortality, morbidity (i.e. 
percentage of animals with dyspnoea and/or fever), percentage of animals with dyspnoea, 
mean number of days during which dyspnoea was observed, percentage of animals with 
fever, mean number of days during which fever was observed, mean percentage of affected 
lung tissue, and logarithmic mean of bacterial titre in caudal lung lobes. 
Fisher's Exact test was used to compare proportions between groups, and the means were 
compared using the non-parametric Wilcoxon rank sum test. 
RESULTS 
Clinical examination 
Disease signs were not observed before challenge and at the time of challenge.  In the 
control group (n = 10), dyspnoea was observed 1 day and 2 days after challenge in 7 and 5 
animals, respectively.  The mean number of days during which dyspnoea was observed was 
1.2 (Table 1).  In 3, 4, 4, 2, 6, and 2 pigs the respiratory rate was increased on days 1, 2, 3, 4, 
5, and 6 after the challenge, respectively.  Sneezing or coughing was observed in all pigs of 
this group.  All animals were depressed the first 3 days after the challenge.  They were seen 
resting on the sternum and it was difficult to force them to move.  Seven animals were still 
depressed 5 days after challenge.  Fever (> 40˚C) was detected in 10, 6, 6, 4, 5, 2, and 1 pig 
on days 1, 2, 3, 4, 5, 6, and 7, respectively.  The mean number of days during which fever 
was observed was 3.4 (Table 1). 
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In the Hemopig™ group (n = 10), 1 pig died 1 day after challenge.  In this pig, dyspnoea and 
coughing had been observed.  In 2 other pigs dyspnoea was observed 1 day after challenge.  
The mean number of days during which dyspnoea was observed was 0.22 (Table 1).  In all 
surviving pigs, an increased respiratory rate was observed the first 2 days after inoculation.  
Coughing was observed in 7 pigs.  Five animals were depressed the first 3 days after 
challenge.  At 1, 2, 3, 4, and 5 days after challenge fever was detected in 5, 5, 4, 4, and 1 pig, 
respectively.  In 3 animals, fever was never detected after challenge.  The mean number of 
days when fever was detected was 1.7 days (Table 1). 
In the Porcilis™ App group (n = 8), 1 pig died 2 days after challenge.  In this pig, dyspnoea 
and fever were present.  Dyspnoea was observed in 1 of the 7 surviving pigs 2 days after 
challenge.  The mean number of days during which dyspnoea was observed was 0.14 days 
(Table 1).  The first 2 days after challenge, an increased respiratory rate was observed in all 
the surviving pigs.  In 5 pigs coughing was detected.  Six pigs were depressed during the first 
2 days after challenge.  Four, 1, 1, and 1 pig developed fever at 1, 2, 3, and 5 days after 
challenge, respectively.  In 3 pigs, fever was not detected.  The mean number of days when 
fever was detected was 1.0 day (Table 1). 
The mean rectal temperatures of the pigs in the control group, the Hemopig™ group, and the 
Porcilis™ App group are compared in Figure 1. 
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Figure 1: Mean body temperatures following challenge with A. pleuropneumoniae serotype 9 
in control pigs (n=10), pigs vaccinated with Hemopig™ (n=10) or Porcilis™ App (n=8). 
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Necropsy findings 
At necropsy, a hæmorrhagic necrotizing pneumonia and fibrinous pleuritis were found in all 
piglets of the control group.  The percentages of affected lung tissue varied from 20% to 73% 
(mean 34.4%; Table 1). 
Lung lesions were not observed in 3 animals of the Hemopig™ group.  In the pig that died, 
58% of the lungs were affected.  In the other animals that developed lung pathology, the 
percentage of affected lung tissue varied from 2 to 56% (mean: 16.1%; Table 1).  The lung 
lesions were characterized by hæmorrhagic necrotizing pneumonia. 
In the Porcilis™ App group, lung lesions were not observed in 3 animals.  In the pig that died, 
51% of the lung tissue was affected.  In the other animals with lung lesions, the percentage of 
affected lung tissue varied between 10% to 35% (mean: 16.9%; Table 1).  Lesions were 
similar to those described above for the Hemopig™ group. 
Bacteriology 
The results are summarized in tables 1 and 2.  In the control pigs, A. pleuropneumoniae was 
isolated from all lung lobes with lesions.  The logarithmic mean bacterial titre of the caudal 
lobes was 1.4x10
6
 CFU/g (Table 1).  A. pleuropneumoniae was isolated from the tonsils of 3 
pigs.  The challenge strain could not be isolated from any of the other samples. 
A. pleuropneumoniae was not isolated from the lungs of 3 animals vaccinated with 
Hemopig™.  The logarithmic mean number of CFU/g lung tissue of the caudal lung lobes was 
2.2x10
3
.  The strain could also be isolated from the tonsils, tracheobronchial lymph nodes, 
and spleen of the pig that died.  A. pleuropneumoniae was not isolated from the other 
samples. 
A. pleuropneumoniae was not isolated from the lungs of 3 animals vaccinated with Porcilis™ 
App.  The logarithmic mean bacterial titre of the caudal lobes was 4.8x10
3
 CFU/g in this 
group.  A. pleuropneumoniae was isolated from the tonsils of the pig that died.  A. 
pleuropneumoniae was not isolated from other samples. 
Serology 
Antibodies against Apx I, Apx II, and Apx III were not detected in sera from pigs of the control 
group and in sera from vaccinated pigs collected at the time of first and second vaccination. 
Antibody titres against Apx I and II at the time of challenge of the vaccinated pigs are 
presented in table 2.  It can be seen that antibody titres against Apx I and II were either low or 
absent.  In none of the animals were antibodies against Apx III detected. 
Statistical analysis 
Significant differences (p <0.05) between the control group and both vaccinated groups were 
found for the mean number of days during which dyspnoea was observed, the mean number 
of days during which fever was detected, the mean percentage of affected lung tissue, and 
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the logarithmic mean bacterial titre in the caudal lung lobes (Table 1).  Significant differences 
could not be demonstrated between the vaccinated groups. 
 
 
 
 
Table 1: Results of endobronchial challenge with A. pleuropneumoniae serotype 9 in pigs 
vaccinated with Hemopig™ or Porcilis™ App and in non-vaccinated control pigs 
 
Control group 
(n = 10) 
Hemopig™ group 
(n = 10) 
Porcilis™ group 
(n = 8) 
mortality (%)  
0 
 
10 
 
13 
morbidity(1) (%)  
100 
 
100 
 
100 
animals with dyspnoea (%)  
70 
 
30 
 
25 
mean number of days with 
dyspnoea(2) 
 
1.20 
 
0.22  * 
 
0.14  * 
animals with fever(3) (%)  
100 
 
60(4)  * 
 
63  * 
mean number of days with 
fever 
 
3.4 
 
1.7  * 
 
1.0  * 
mean % of affected lung 
tissue 
 
34.4 
 
16.1  * 
 
16.9  * 
mean bacterial titre in caudal 
lung lobes(5) (CFU) 
 
1.4x106 
 
1.7x103  * 
 
4.8x103  * 
(1). morbidity: % of animals with increased respiratory rate and/or fever 
(2). only pigs that survived challenge were included 
(3). fever: body temperature 40°C 
(4). one animal died approximately 27 hours after infection.  Temperature was only  
       taken once.  Fever was not observed. 
(5). logarithmic mean: values of <100 CFU/g lung tissue were considered 101 
* significant difference with control group (p <0.05) 
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Table 2: Results of pathology, serology, and bacteriology in pigs vaccinated with Hemopig™ or Porcilis™ App and in non-vaccinated animals after challenge with A. pleuropneumoniae serotype 9 
 
Group 
 
pig nr 
antibody titre at the time of challenge against Isolation of A. pleuropneumoniae Bacterial titre in caudal lung lobes % of affected lung tissue 
  Apx I Apx II from lungs (CFU/gram)  
 1 <20 <20 yes 4.0x103 20 
 2 <20 <20 yes 4.5x107 47 
 3 <20 <20 yes 1.3x106 30 
 4 <20 <20 yes 4.7x106 28 
Control 5 <20 <20 yes 2.0x103 30 
 6 <20 <20 yes 2.0x105 20 
 7 <20 <20 yes 1.0x107 38 
 8 <20 <20 yes 2.2x108 27 
 9 <20 <20 yes 6.5x107 32 
 10 <20 <20 yes 3.4x105 73 
 11 <20 <20 yes <102 7 
 12 <20 <20 yes 3.3x105 13 
 13 <20 <20 yes 8.0x107 58 
 14 20 <20 no <102 0 
Hemopig 15 <20 <20 yes 5.0x104 12 
 16 <20 <20 yes 4.0x104 56 
 17 80 40 no <102 0 
 18 <20 <20 no <102 0 
 19 <20 <20 yes 5.1x104 12 
 20 <20 <20 yes <102 2 
 21 20 <20 yes 1.7x106 51 
 22 20 <20 yes 4.6x106 22 
 23 20 <20 yes 1.2x103 10 
Porcilis 24 20 <20 no <102 0 
 25 20 <20 yes 1.5x105 35 
 26 <20 <20 no <102 0 
 27 <20 <20 yes 2.0x105 16.0 
 28 40 <20 no <102 0 
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DISCUSSION 
In the present study, an endobronchial challenge model was used.  An advantage of this 
method is that it delivers an exact number of bacteria to the lungs, allowing standardization of 
experimental infections. 
All control pigs developed acute disease and at necropsy, macroscopic pulmonary lesions 
typical of porcine pleuropneumonia were observed.  None of these animals died, indicating 
that the challenge model was of planned severity. 
The clinical signs of disease persisted for a shorter time in the vaccinated than in the control 
animals.  Furthermore, lesions were more severe and the mean bacterial titre in lung tissue 
was higher in control animals, indicating partial protection in both vaccinated groups. 
Although both vaccines contained Apx toxins, no or only low neutralizing antibody titres were 
detected in vaccinated animals.  The reason for this finding is not clear.  Interference with 
maternally derived antibodies can most probably be excluded, since the first vaccination was 
carried out at 19 weeks of age and antibodies against Apx toxins were not detected at the 
time of first vaccination.  It is possible that the assay used here is of limited sensitivity, but in 
previous studies with the same assay, high toxin-neutralizing titres were detected in pigs 
infected with virulent A. pleuropneumoniae strains (Haesebrouck et al., 1996).  In the latter 
studies, animals were completely protected against challenge with the homologous serotype.  
Further research is necessary to develop vaccines that induce high Apx toxin-neutralizing 
antibody titres. 
It has been shown that the Apx toxins are essential vaccine components to confer protection 
against challenge with pathogenic A. pleuropneumoniae (Beaudet et al., 1994; Byrd et al., 
1992; Van den Bosch et al., 1992).  Although both vaccines used in the present study 
contained Apx toxins, they provided only partial protection against challenge carried out 3 
weeks after the second vaccination.  These results and the results of previous studies 
indicate that other bacterial components may also play a role in protection (Haesebrouck et 
al., 1996) and/or that higher titres are required for protection.  It is possible that antibodies 
against the Apx toxins decrease the severity of the disease and allow animals to recover 
faster but do not prevent the initial infection.  This might require antibodies against other 
bacterial compounds. 
In the present studies, the protection obtained with the Porcilis™ App vaccine was lower than 
the protection described by Kobisch and Van den Bosch (1992) and Van den Bosch et al. 
(1992).  In the latter studies, SPF pigs were used whereas in the study described here, 
conventional pigs were used.  It is possible that protection induced in conventional pigs is 
more variable than that induced in SPF pigs. 
In only 5 of the 28 animals was the challenge strain isolated from tonsils.  The isolation of A. 
pleuropneumoniae from tonsils, however, is difficult.  The media used for the isolation are 
often overgrown by the abundant microflora present in the tonsils.  This complicates visual 
identification. 
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SUMMARY 
The efficacy of a subunit vaccine containing the Apx toxins of Actinobacillus 
pleuropneumoniae and transferrin binding proteins was determined. Ten pigs were 
vaccinated twice with the vaccine.  Eight control animals were injected twice with a saline 
solution.  Three weeks after the second vaccination, all pigs were endobronchially inoculated 
with 10
6.5
 colony-forming units (CFU) of an A. pleuropneumoniae serotype 9 strain.  In the 
vaccine group, none of the pigs died after inoculation.  Only one pig of the control group 
survived challenge.  Surviving pigs were killed at 7 days after challenge.  The mean 
percentage of affected lung tissue was 64% in the control group and 17% in the vaccine 
group.  A. pleuropneumoniae was isolated from the lungs of all animals.  The mean bacterial 
titres of the caudal lung lobes were 5.0x108 CFU/g in the control group and 3.0x106 CFU/g in 
the vaccine group.  It was concluded that the vaccine induced partial protection against 
severe challenge. 
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INTRODUCTION 
A. pleuropneumoniae causes porcine contagious pleuropneumonia, which is distributed world 
wide and results in serious losses in the pig rearing industry.  It also causes severe animal 
suffering.  The disease is characterized, in the acute stage, by a hemorrhagic necrotizing 
pneumonia and fibrinous pleuritis.  In the chronic stage, localized lung lesions and adhesive 
pleuritis can be seen (Nicolet, 1992).  For control of porcine pleuropneumonia, improving 
housing conditions and climate is essential.  To control outbreaks of this disease, vaccination 
may be useful.  Although the so-called “first generation vaccines” of whole-cell bacterins may 
reduce mortality after infection with the homologous serotype, they generally do not confer 
protection against challenge with heterologous serotypes (Fenwick and Henry, 1994).  An 
explanation for the limited protection might be the absence of secreted and certain bacteria-
associated virulence factors in the bacterins.  So-called “second generation vaccines” i.e. 
vaccines containing the A. pleuropneumoniae Apx toxins have become commercially 
available. Among the different serotypes of A. pleuropneumoniae, three of these exotoxins 
have been described and each serotype produces either one or two of them (Dom et al., 
1994; Frey et al., 1993; Frey et al., 1994; Kamp et al., 1991).  In a recent study, we 
demonstrated partial protection against endobronchial challenge in animals vaccinated twice 
with two second generation vaccines (Chiers et al., 1998) .  Field trials carried out in France 
(Pommier et al., 1996), the Netherlands (Valks et al., 1996), Italy (Martelli et al., 1996), Spain 
(López et al., 1998) and Norway (Lium et al., 1998) confirmed that vaccination with these 
vaccines can result in reduction of clinical symptoms and lung lesions of acute and chronic 
pleuropneumonia and improvement of performance (growth, feed conversion, cost of 
medication).   
Apx toxins are not the only antigens involved in protection against porcine pleuropneumonia.  
Capsular antigens, cell wall lipopolysaccharides, outer membrane proteins, fimbriae and 
transferrin binding proteins also play a role (Haesebrouck et al., 1997). 
In the present study, the efficacy of a vaccine, containing several recombinant cell-associated 
and secreted antigens of A. pleuropneumoniae including the Apx toxins and transferrin 
binding proteins, was determined using a severe, well standardized challenge model (Dom 
and Haesebrouck, 1992; Haesebrouck et al., 1996). 
MATERIALS AND METHODS 
Challenge strain 
An A. pleuropneumoniae biotype 1-serotype 9 strain (N° 13261) was used (Smits et al., 
1991).  Bacteria were grown for 6 hours (log phase of growth) on Columbia agar (Columbia 
Agar Base, Lab M, Bury, Great Britain) supplemented with 3% horse serum, 0.03% NAD 
(Sigma Chemical Co, St Louis, Mo, USA), and 5% yeast extract at 37°C in a humid 
atmosphere with 5% CO2.  Bacteria were harvested in phosphate-buffered saline solution 
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(PBSS, pH 7.3), centrifuged at 400 x g for 20 minutes, and suspended in RPMI 1640 
supplemented with 10% non-essential amino acids, 10% glutamine, 10% foetal calf serum, 
and 1% sodium pyruvate.  The suspension was checked for purity and the number of colony-
forming units (CFU) was determined by plating tenfold dilutions on Columbia agar 
supplemented with 3% horse serum, 0.03% NAD, and 5% yeast extract.  Bacterial 
suspensions were stored overnight at 4°C.  The next day, they were used in the experiments. 
Pigs 
In this study 18 pigs were used.  All animals were obtained by using a medicated segregated 
early weaning programme (Chiers et al., 1998).  They were weaned at 18 days of age and 
kept in isolation until used in the experiments. 
Vaccine 
An acellular pentavalent subunit vaccine prepared with recombinant antigens from A. 
pleuropneumoniae was used (Pleurostar, Biostar Inc., Saskatoon, Canada).  It contains 
transferrin binding proteins and Apx toxins.  
Experimental design 
At the age of 7 and 11 weeks, pigs were intramuscularly injected: 10 pigs with 2 ml of the 
vaccine and 8 pigs with 2 ml of a saline solution.  Three weeks after the second vaccination, 
all pigs were experimentally infected.  The pigs were anaesthetized with Zoletil 100 (2.2 
mg/kg tiletamine and 2.2 mg/kg zolazepam, Virbac, Louvain La Neuve, Belgium) and Xyl-M 
2% (4.4 mg/kg xylazin, VMD, Arendonk, Belgium).  They were inoculated endobronchially 
with 10
6.5
 CFU of the challenge strain in 5 ml inoculum (Dom and Haesebrouck, 1992; 
Haesebrouck et al., 1996).  All pigs were examined clinically.  Pigs that died were autopsied 
immediately; those that survived the challenge were killed 7 days after inoculation.  At 
necropsy, the lungs were examined macroscopically and the percentage of affected lung 
tissue was determined.  For this purpose, a diagram was used that divides the lung into 74 
equal triangles (Hannan et al., 1982).  The percentage of affected lung tissue was determined 
by summing up the triangles showing pneumonia and/or pleuritis divided by 74.  Samples 
from lungs, tracheobronchial lymph nodes, tonsils, liver, kidney, and spleen were taken for 
bacteriological examination.  Sera were collected before the first and the second vaccination 
and before the challenge. 
Clinical examination 
The pigs were examined for signs of pneumonia, characterized by increased respiratory rate 
(>40 inspirations/min), dyspnoea, sneezing, coughing, and the presence of bloody foam on 
mouth and/or nostrils.  Rectal temperature was measured 1 day before challenge inoculation, 
just before inoculation, and during the 7 days after inoculation.  Other indications of infection 
were vomiting and a depressed appearance. 
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Bacteriological examination 
Twenty per cent (w/v) suspensions of the right and the left caudal lung lobes were made in 
PBSS.  The number of CFU was determined by plating tenfold dilutions of the suspensions on 
Columbia agar supplemented with 3% equine serum, 0.03% NAD and 5% yeast extract.  
Samples were also grown on Columbia agar supplemented with 5% bovine blood with a 
Staphylococcus intermedius streak.  Twenty per cent (w/v) suspensions of tonsils were made 
in PBSS and inoculated onto blood agar with S. intermedius.  Suspected colonies were 
subcultured on the same medium.  Samples from lung lesions, tracheobronchial lymph nodes, 
liver, kidney and spleen were tested for the presence of A. pleuropneumoniae by making an 
incision in these tissues and taking a sample with an inoculation loop.  These samples were 
also inoculated onto blood agar with S. intermedius. 
Serology 
All pig sera were tested for presence of neutralising antibodies against Apx I, II and III using a 
bioassay based on neutral red uptake by viable pulmonary alveolar macrophages, as 
described previously (Dom et al., 1994). 
Statistical analysis 
Statistical analysis was performed on the following variables: mortality, morbidity (i.e. 
percentage of animals with dyspnoea and/or fever), percentage of animals with fever, 
percentage of animals with dyspnoea, mean percentage of affected lung tissue and 
logarithmic mean of bacterial titre in caudal lung lobes.  Fisher’s exact test was used to 
compare proportions between groups.  The mean percentages of affected lung tissue were 
compared using the non-parametric Kruskal-Wallis test and the mean bacterial titres in caudal 
lung lobes were compared using an ANOVA test. 
RESULTS 
Results are summarized in Table 1. 
Clinical examination 
None of the animals showed disease signs before challenge and at the time of challenge.  In 
the control group (n=8), six pigs were found dead 20 h after inoculation.  One pig died 48h 
after inoculation.  In this pig, fever, dyspnoea, coughing and depression were present.  The 
remaining pig presented fever (>40°C), increased respiratory rate and coughing during 6 days 
after challenge and was depressed on day 2.   
In the vaccinated group (n=10), none of the pigs died after inoculation.  In 1, 1, 4 and 1 pig, 
fever was detected during 1, 2, 5 and 6 days after challenge, respectively.  The mean number 
of days during which fever was observed was 3.1.  In 4, 1 and 1 pigs, increased respiratory 
rate was observed during 1, 2 and 3 days, respectively.  None of the animals showed 
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dyspnoea.  In four pigs occasional coughing was observed.  One animal with increased 
respiratory rate was depressed. 
Necropsy findings 
In all animals lung lesions, when present, were characterized by a haemorrhagic necrotizing 
pneumonia and fibrinous pleuritis .   
In 7 animals of the control group more than 45% of the lung tissue and in one animal 31% of 
the lung tissue was affected (variation 31-88%; mean: 64%).   
In eight animals of the vaccinated group the % of affected lung tissue was lower than 20%.  In 
two animals more than 45% of the lung tissue was affected.  The percentages of affected lung 
tissue varied from 4% to 53% (mean 17%).  
Bacteriology 
The results are summarized in Table 1.   
In the control pigs, A. pleuropneumoniae was isolated from all lung lobes with lesions.  The 
number of CFU/gram lung tissue of the caudal lobes varied between 4.0 x 106 and 4.5 x 109, 
with a logarithmic mean of 5.0 x 108.  The challenge strain was isolated from the tonsils and 
tracheobronchial lymphnodes of 8 and 5 pigs, respectively.  A. pleuropneumoniae was not 
isolated from liver, spleen or kidney of any animals in this group. 
A. pleuropneumoniae was isolated from all lung lobes with lesions and from all tonsils of the 
vaccinated animals.  The number of CFU/gram lung tissue of the caudal lobes varied between 
2.7 x 104 and 1.1 x 108, with a logarithmic mean of 3.0 x 106. A. pleuropneumoniae was not 
isolated from tracheobronchial lymphnodes, liver, spleen or kidney of any animals in this 
group.  
Serology 
At the time of first vaccination, antibody titres against Apx I, II and III varied between <20 and 
80.  At the time of second vaccination, most animals were negative for antibodies against the 
Apx toxins.  Low titres (20) were detected in 2 and 3 animals of the control and vaccinated 
group, respectively.  Antibody titres against Axp I, II and III at the time of challenge varied 
between <20 and 40.  
Statistical analysis 
The vaccinated group differed significantly (p<0.05) from the control group for mortality, 
percentage of animals with dyspnoea, percentage of affected lung tissue and logarithmic 
mean of bacterial titre in the caudal lung lobes. 
 
 
 
 
Experimental studies 
 59
Table 1.  Results of endobronchial challenge with A. pleuropneumoniae serotype 9 in 
vaccinated pigs and in non-vaccinated control pigs 
 Control group 
(n=8) 
vaccine group 
(n=10) 
morbidity(1) (%) 100 70 
mortality (%) 88 0* 
% animals with dyspnoea(2) 100 0* 
% animals with fever (2, 3) 100 70 
mean % of affected lung tissue 64 17* 
mean bacterial titre in caudal lung lobes (CFU/g) 5.0 x 108 3.0 x 106* 
(1) morbidity: % of animals with increased respiratory rate and/or fever 
(2) only pigs that survived more than 24 hours after challenge were included 
(3) fever: body temperature ≥ 40°C 
* significant difference with control group (p<0.05) 
 
Table 2.  Results of pathology, serology and bacteriology in vaccinated pigs and in non-
vaccinated control animals after challenge with A. pleuropneumoniae serotype 9 
 
Group pig nr antibody titre at the time of 
challenge against  
    Apx I          Apx II        Apx III 
Bacterial titre in 
caudal lung lobes 
(CFU/gram) 
% of affected 
lung tissue 
Control 1 
2 
3 
4 
5 
6 
7 
8 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
4.0 x 106 
1.0 x 109 
1.9 x 109 
4.5 x 109 
2.2 x 109 
6.8 x 107 
5.4 x 108 
1.3 x 109 
75 
57 
88 
71 
54 
76 
60 
31 
       
Vaccinated 18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
<20 
<20 
20 
<20 
20 
40 
40 
40 
40 
40 
20 
20 
20 
40 
20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
<20 
3.1 x 107 
5.2 x 105 
1.1 x 108 
2.0 x 106 
2.7 x 104 
1.5 x 107 
3.4 x 105 
2.5 x 107 
3.0 x 105 
3.5 x 107 
7 
4 
17 
5 
5 
53 
5 
45 
11 
18 
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DISCUSSION 
Intranasal inoculation or aerosol exposure closely resemble the natural infection route of A. 
pleuropneumoniae.  These methods are difficult to standardize, however, because coughing, 
sneezing, swallowing, breathing and mucociliary clearance can reduce the number of bacteria 
that reach the alveolar region.  In the present study, an endobronchial challenge model was 
used.  An advantage of this model is that it delivers an exact number of bacteria into the 
bronchi, allowing standardization of experimental infections.  Furthermore, this method allows 
us to bring the bacteria directly close to the multiplication site of A. pleuropneumoniae namely 
the alveoli and bronchioli (Haesebrouck et al., 1997).  A possible disadvantage is that the 
challenge strain is applicated not all over the lung but given more focal.  Endobronchial 
challenge is therefore more likely to break through low level immunity in the respiratory tract 
than a more natural challenge route.   
Seven of the 8 control animals died within 48 hours after infection.  This demonstrates that a 
severe challenge model was used. 
None of the vaccinated animals died and none of them developed dyspnoea.  Furthermore, 
the mean % of affected lung tissue and the mean bacterial titre in the caudal lung lobes were 
significantly lower than in the control animals.  This indicates that this vaccine induced partial 
protection against severe challenge. 
It has been shown that the Apx toxins are essential vaccine components to confer protection 
against challenge with A. pleuropneumoniae (Beaudet et al., 1994; Byrd et al., 1992; Van den 
Bosch et al., 1992).  However, in a previous study using a milder challenge model resulting in 
no mortality in non-vaccinated control pigs, animals vaccinated with vaccines containing Apx 
toxins were only partially protected against A. pleuropneumoniae serotype 9.  It was 
suggested that antibodies against other bacterial components are also required for protection 
(Chiers et al., 1998).  The vaccine used in the present studies also contained transferrin 
binding proteins and induced significant protection against a very severe challenge.  This 
finding is in agreement with a study performed by Rossi et al. (1992).  They found that pigs 
vaccinated with a recombinant protein subunit vaccine containing Apx II toxin and a 
transferrin binding protein of an A. pleuropneumoniae serotype 7 strain showed only minimal 
clinical signs or lung lesions after a homologous challenge.  
Although the vaccine contained Apx toxins, only low neutralizing antibody titres were detected 
in the vaccinated animals.  The reason for this finding is not clear.  Interference with 
maternally derived antibodies can not be excluded, since the first vaccination was carried out 
at 7 weeks of age and low antibody titres against Apx toxins were detected at the time of first 
vaccination.  Furthermore, it is possible that the assay used here was of limited sensitivity, 
although in previous studies with the same assay, high toxin-neutralizing titres were detected 
in pigs infected with virulent A. pleuropneumoniae strains (Haesebrouck et al., 1996).  In the 
latter studies, animals were completely protected against challenge with the homologous 
serotype.  Further research is necessary to develop vaccines that induce high Apx toxin-
neutralizing antibody titres. 
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In the present studies, animals were only challenged with a serotype 9 strain.  Since Apx 
toxins and transferrin binding proteins were included in the vaccine, protection against other 
serotypes can be expected (Van den Bosch et al., 1992; Wilke et al., 1997).  This should, 
however, be confirmed in challenge studies with other serotypes. 
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SUMMARY 
A. pleuropneumoniae biovar 1 serotype 2, 5a, 9 and 10 strains were tested for their ability to 
adhere to alveolar epithelial cells in culture.  For the serotype 5a, 9 and 10 strains, optimal 
adherence was observed after growth of bacterial cells in a NAD-restricted medium (0.001% 
NAD).  This condition was also associated with the expression of a 55 kDa outer membrane 
protein and of fimbriae.  For the serotype 2 strain, adherence and expression of fimbriae and 
a 55 kDa outer membrane protein was less influenced by the growth conditions.  The N-
terminal amino acid sequence of the 55 kDa outer membrane protein had no homology with 
any known sequence, suggesting that it is an as yet unknown protein.  Adherence capabilities 
were significantly reduced following treatment of the bacteria with proteolytic enzymes or 
heat.  These findings suggest that proteins are involved in adhesion.  The hydrophobic bond 
breaking agent tetramethylurea was unable to inhibit the adherence of A. pleuropneumoniae 
to alveolar epithelial cells.  Treatment of the bacteria with sodium metaperiodate resulted in 
lower adhesion scores for the serotype 2 and 9 strains but the inhibition of adhesion was 
clearly lower than after treatment with proteolytic enzymes.  This indicates that, besides 
proteins, carbohydrates might also be involved in adhesion of A. pleuropneumoniae to 
alveolar epithelial cells. The finding that inhibition of adhesion was very high when bacteria 
were treated with a combination of sodium metaperiodate and pronase also suggests that 
more than one adhesin is involved.  
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INTRODUCTION 
Actinobacillus pleuropneumoniae is a Gram-negative bacterium causing contagious 
pleuropneumonia in pigs.  Based on NAD requirements, A. pleuropneumoniae can be divided 
into biovar 1 strains, which are NAD-dependent, and biovar 2 strains, which are NAD-
independent.  So far 15 serotypes have been described (Blackall et al., 2002).  Serotypes 1 
and 5 are subdivided into 1a, 1b and 5a, 5b (Jolie et al., 1994; Nielsen, 1986). 
In previous studies, it was shown that A. pleuropneumoniae adheres to the epithelium of the 
alveoli or the cilia of the terminal bronchioli of experimentally infected pigs (Dom et al., 1994).  
It has also been shown that A. pleuropneumoniae adheres to porcine tracheal rings 
maintained in culture (Bélanger et al., 1990), to porcine frozen tracheal and lung sections  
(Jacques et al., 1991), to erythrocytes from various animal species (Jacques et al., 1988), to 
tonsillar epithelial cells (Chiers et al., 1999), to swine buccal epithelial cells (Hamer et al., 
1999) and to type III swine-lung collagen (Enriquez et al., 1999). 
Adherence to host tissue is generally regarded as an important prerequisite for colonization 
and virulence manifestation of bacteria (Ofek and Beachy, 1980).  Adherence enables 
colonization to occur and allows the bacterium to exert its pathogenic effects.  Several surface 
structures have been described in the family of Pasteurellaceae that are involved in adhesion, 
including the capsule (Confer et al., 1995), fimbriae (Read et al., 1992), lipopolysaccharides 
(Bélanger et al., 1990) and outer membrane proteins (Confer et al., 1995).  Concerning A. 
pleuropneumoniae, only few adhesion factors have been described.  Lipopolysaccharides 
seem to be involved in the in vitro adhesion to porcine tracheal rings (Bélanger et al., 1990) 
and mucus (Bélanger et al., 1992; 1994).  Recently, it was shown that the capsule is not 
responsible for adherence to tracheal frozen sections (Jacques, 1999).  Type 4 fimbriae have 
been shown on A. pleuropneumoniae (Dom et al., 1994a; Zhang et al., 2000) but their role in 
adherence needs to be elucidated. 
Since in vivo studies indicated that adherence of A. pleuropneumoniae to alveolar epithelial 
cells constitutes an important initial step in pathogenesis (Dom et al., 1994; Haesebrouck et 
al., 1997), the association of the bacterium with these host cells was here further 
characterized, using an in vitro adhesion model. 
MATERIALS AND METHODS 
Bacterial strains and culture conditions 
Reference strains of A. pleuropneumoniae serotype 9 (13261) and 10 (D13039), as well as a 
serotype 2 (266/7656) and 5a (1736) strain, both obtained from the lungs of pigs that died 
during outbreaks of pleuropneumonia in Belgium (Dom et al., 1994b), were used in this study.  
All 4 strains were NAD-dependent (biovar 1).  Stock suspensions were stored at -70°C in 
RPMI 1640 medium supplemented with 10% non-essential amino acids (Gibco Europe, 
Merelbeke, Belgium), 10% glutamine, 10% foetal calf serum (FCS) and 1% sodium pyruvate 
(Gibco) (leukocyte medium).  To study the influence of culture conditions on adhesion, 
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bacteria were grown on Columbia agar supplemented with 1% horse serum and 0.001% NAD 
for 20 hours at 37°C (NAD-restricted medium), on Columbia agar supplemented with 3% 
horse serum, 0.001% NAD and 5% yeast extract for 20 hours at 37°C (NAD-restricted 
medium with yeast extract) or on Columbia agar supplemented with 3% horse serum, 0.03% 
NAD and 5% yeast-extract for 6 hours at 37°C (NAD-rich medium).  To study the expression 
of surface antigens, bacteria were grown on the NAD-restricted and NAD-rich media 
described above.  In all other studies, bacteria were grown for 20 hours on the NAD-restricted 
medium.  All incubations were done in an atmosphere with 5% CO2.  The number of colony 
forming units (CFU) was determined by turbidimetry (optical density at 450 nm). 
Adherence assay 
Alveolar epithelial cells (AEC) were obtained as previously described (Van de Kerkhof et al., 
1996).  For the adherence assay, 105 viable cells in 100 µl of supplemented Modified Eagle 
Medium (MEM, Gibco) were added to wells of 24-well microtiter plates with coverslips and 
incubated for 3 hours at 37°C in an atmosphere with 5% CO2.  Then, 1 ml of supplemented 
MEM was added to each well and the plates were further incubated for 2 days.  
Subsequently, plates were washed once with phosphate buffered saline solution (PBSS) and 
cells were fixed with 1 ml of methanol 100%.  After washing the cells with distilled water, 
adhesion tests were performed.  In these tests, 108 CFU of the A. pleuropneumoniae strains 
in 1 ml inoculum were added to the cultures.  The microtiter plates were centrifuged at 110×g 
for 10 minutes at 37°C and further incubated at 37°C for 30 minutes in an atmosphere with 
5% CO2.  The plates were washed 4 times with PBSS, stained with Haemacolor® staining 
reagents (Merck, Darmstadt, Germany) and microscopically examined.  
In each assay, one hundred cells were examined for the presence of adhering bacteria.  The 
following scores were used for each alveolar epithelial cell: score 0 = no adhesion, score 1 = 
1 to 20 bacteria adhered to the cell, score 2 = more than 20 bacteria adhered to the cell.  The 
number of alveolar epithelial cells with score 0, 1 or 2 was determined. 
Influence of culture conditions on adhesion to AEC and expression of capsule, 
fimbriae and outer membrane proteins 
Influence of culture conditions on adhesion 
To study the influence of the culture conditions on adhesion, adhesion tests were performed 
with A. pleuropneumoniae serotype 2, 5a, 9 and 10 strains grown on either the NAD-restricted 
medium, NAD-restricted medium with yeast extract or NAD-rich medium.  These experiments 
were performed at least 3 times. 
Influence of culture conditions on expression of capsule 
A. pleuropneumoniae serotype 2, 5a and 9 strains were grown on the NAD-restricted and the 
NAD-rich medium.  After incubation, bacteria were harvested, washed once with PBSS and 
resuspended in PBSS at a concentration of 108 CFU/ml.  In order to avoid collapse of the 
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capsules during the electron microscopic examination, bacterial suspensions were exposed to 
undiluted homologous antiserum for 1 hour at 4°C.  The antisera were raised in rabbits 
against whole bacterial cells. The titers of agglutinating antibodies of the rabbit antisera varied 
between 1:8 and 1:32 (Russel W.M.S. and Burch R.L., 1959).  Bacterial cells were then 
suspended in cacodylate buffer (0.1M, pH 7.0) containing 5% glutaraldehyde and 0.15% (w/v) 
ruthenium red.  Fixation was done for 2 hours at 20°C.  Thereafter, bacterial cells were 
immobilized in 3% agar, washed five times in cacodylate buffer with 0.05% ruthenium red and 
postfixed with 1% osmium tetroxide and 0.05% ruthenium red for 2 hours.  Washings were 
repeated as above, and the samples were dehydrated in a graded series of acetone washes.  
All the solutions used in processing the specimen, from the wash after glutaraldehyde fixation 
to dehydration with the 70% acetone solution, contained 0.05% ruthenium red.  Samples were 
then washed twice in propylene oxide and embedded in Spurr low-viscosity resin.  Thin 
sections were cut and stained with uranyl acetate and lead citrate.  They were examined with 
a transmission electron microscope (Philips 201) at an accelerating voltage of 60 kV.  The 
capsule thickness was measured on micrographs taken during the electron microscopic 
observations.  The cell wall thickness was measured between the inner edge of the capsule 
layer and the outer leaflet of the plasma membrane. 
Influence of culture conditions on expression of fimbriae 
A. pleuropneumoniae serotype 2, 5a, 9 and 10 strains were grown on the NAD-restricted and 
the NAD-rich medium, washed once in PBSS and then suspended in a minimal amount of 
distilled water at a concentration of 108 CFU/ml.  The cultures were examined for the 
presence of fimbriae by negative staining and shadowing.  For negative staining, a Formvar-
coated copper grid was floated on the surface of the bacterial suspension for 10 minutes.  
The grid was then floated for 10 seconds on a solution of 2% uranyl acetate in distilled water.  
After staining, the grid was washed twice and examined with a Philips 201 transmission 
electron microscope (TEM).  For shadowing, the bacterial suspension was absorbed on 
carbon coated grids and rotary shadowed with platinum-carbon at a small angle (5-6°) with 
the Balgers shadowing apparatus.  The grid was examined with a Philips 201 TEM.  The size 
of the fimbriae was measured on the micrographs taken during electron microscopic 
observations. 
Influence of culture conditions on expression of outer membrane proteins 
Sarcosyl insoluble outer membrane proteins (OMPs) of A. pleuropneumoniae serotype 2, 5a, 
9 and 10 strains grown on the NAD-restricted and the NAD-rich medium were prepared 
(Deneer and Potter, 1989).  Briefly, bacteria were suspended in 100 ml of 10 mM HEPES 
buffer (pH 7.5, Gibco, Ghent, Belgium) at a concentration of 2×109 CFU/ml.  Cells were 
disrupted by ultrasound with 10 bursts, 20 seconds each, with cooling on ice.  Debris was 
removed by centrifugation at 2,000×g for 20 minutes and 50 ml 2% (w/v) sarcosyl (Sigma 
Chemical Co, St Louis, Mo, USA) was added to the supernatant.  After incubation for 10 
minutes at room temperature, the outer membrane fraction was pelleted by centrifugation at 
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60,000×g for 1 hour and 40 minutes.  The pellet was suspended in 10 ml 10 mM HEPES 
buffer and treated with 10 ml 2% sarcosyl for 20 minutes at room temperature.  The OMP 
fraction was again pelleted by centrifugation at 60,000×g for 1 hour and 40 minutes and 
suspended in 1 ml of 10mM HEPES.  Before storage at -70°C, the protein concentration was 
determined (BIORAD Protein Assay, BIORAD, Brussels, Belgium).  After thawing, proteins (5 
µg) of each sample were separated using discontinuous sodium dodecylsulphate 
polyacrylamide gel electrophoresis (SDS-PAGE).   
Electrophoresis experiments were performed with a 4.5% stacking gel and a 12% running gel.  
Each antigen preparation was mixed with equal volumes of solubilization buffer [4% (w/v) of 
SDS, 10% (v/v) 2-mercapto ethanol, 17.4% (v/v) glycerol and 0.01% bromophenol blue in 
0.06M Tris HCl (pH 6.8)] and boiled for 5 minutes prior to electrophoresis.  After 
electrophoresis, silver staining was performed (Morrissey J., 1981). 
N-terminal amino acid sequence analysis of an outer membrane protein 
The OMPs of the A. pleuropneumoniae serotype 5a and 10 strains grown on the NAD-
restricted medium were separated by SDS-PAGE, blotted onto a polyvinylidene difluoride 
membrane and stained with Coomassie blue.  A 55 kDa OMP band was cut out and put in a 
blotcartridge (cross-flow type).  The N-terminal amino acid sequence was determined in an 
automatic pulsed liquid phase sequencer (model 476, PE Biosystems, Foster City, Ca) using 
the Edman degradation method.  Thereafter, a BLAST (Basis Local Alignment Search Tool) 
search was performed in the following databases: non-redundant GenBank CDS translations, 
PDB, SwissProt, Spupdate and PIR. 
Effect of pretreatment of bacterial cells with enzymes, heat, sodium metaperiodate, 
tetramethylurea and carbohydrates on adhesion to alveolar epithelial cells 
A. pleuropneumoniae serotype 2, 5a and 9 strains were grown on the NAD-restricted medium 
and suspended in PBSS at a concentration of 108 CFU/ml.  The suspensions were subjected 
to the following treatments: (1) bacteria were incubated for 30 minutes at 37°C with pepsin 
solution [1 mg/ml pepsin in 50 mM citrate-10 mM phosphate buffer (pH 3)]; (2) bacteria were 
incubated for 1 hour at 37°C with trypsin solution [1 mg/ml trypsin in PBSS (pH 7.5)].  
Thereafter, the activity of trypsin was stopped by adding soybean trypsin inhibitor (200 U/ml; 
Sigma) in a sodium phosphate buffer (pH 7.6); (3) bacteria were incubated for 1 hour at 37°C 
in PBSS (pH 7.3) followed by an incubation for 40 minutes at 37°C in pronase solution [0.01M 
sodium acetate and 0.005M calcium acetate buffer (pH 7.5) containing 1 mg/ml pronase]; (4) 
bacteria were incubated for 1 hour at 37°C in a sodium metaperiodate solution [10 mg/ml 
sodium metaperiodate in PBSS (pH 7.3)] followed by an incubation for 40 minutes at 37°C in 
the sodium acetate and calcium acetate buffer without pronase; (5) bacteria were incubated 
for 1 hour at 37°C in the sodium metaperiodate solution followed by an incubation for 40 
minutes at 37°C in the pronase solution; (6) bacteria were heated at 56°C for 10, 20 or 30 
minutes; (7) bacteria were incubated for 1 hour at 37°C with the following carbohydrates: D-
Experimental studies 
 73
arabinose, D-maltose, D-saccharose, D-mannose, D-glucosamine, D-galactose, N-acetyl-D-
galactosamine, D-xylose or D-glucose (all carbohydrates at a final concentration of 0.2M); (8) 
bacteria were incubated for 1 h at 37°C with 0.01M of the hydrophobic bond-breaking agent 
1, 1, 3, 3-tetramethylurea (TMU; Sigma Chemical Co., St. Louis, MO, USA.). 
Controls consisted of non-heat treated bacteria or bacteria incubated in the buffers without 
pepsin, trypsin, pronase, sodium metaperiodate, carbohydrates or tetramethylurea.  After the 
treatments with pepsin, trypsin, pronase, sodium metaperiodate or carbohydrates, bacterial 
suspensions were washed in PBSS, resuspended with PBSS to 108 bacteria/ml and used in 
the adhesion tests.  After the treatment with tetramethylurea, adhesion tests were performed 
in the presence of tetramethylurea. 
For each treatment, after incubation, the influence on the viability of the bacterial cells was 
determined by plating tenfold dilutions on Columbia agar supplemented with 3% horse serum, 
0.03% NAD and 5% yeast extract and comparing the number of CFU/ml with controls. 
All parts of the experiment were performed at least 2 times. 
Statistical analysis 
The influence of the culture conditions and the different pretreatments of the bacterial cells on 
adhesion were compared with the Kruskal-Wallis one way non-parametric analysis of 
variance test (computer program STATISTIX 4.1, Analytical software).  A significance level of 
0.05 was used.  
RESULTS 
Influence of culture conditions on adhesion and expression of capsule, fimbriae and 
outer membrane proteins 
Influence of culture conditions on adhesion 
The number of alveolar epithelial cells with adhesion scores 0, 1 or 2 is given in Table 1 for A. 
pleuropneumoniae serotype 2, 5a, 9 and 10 strains grown on the NAD-rich medium, the NAD-
restricted medium and the NAD-restricted medium with yeast extract.  For the serotype 5a, 9 
and 10 strains, adhesion scores were significantly higher when bacteria were grown on both 
NAD-restricted media.  For the serotype 2 strain, there was no significant difference in 
adhesion scores between the growth conditions.   
Bacteria did not cover the whole surface of the alveolar epithelial cells; they only surrounded 
the alveolar epithelial cells (Figure 1). 
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Table 1. Influence of culture conditions on adhesion of A. pleuropneumoniae serotype 2, 5a, 9 and 10 strains to porcine alveolar epithelial cells. 
Serotype Growth conditions 
Total number of 
alveolar epithelial 
cells 
Number (%) of alveolar epithelial cells with score: 
0 
0 bacteria adhering 
1 
1-20 bacteria adhering 
2 
>20 bacteria adhering 
2 
NAD-restricted 700 0    (0) 83 (12) 617 (88) 
NAD-restricted with yeast extract 300 0    (0) 4   (1) 296 (99) 
NAD-rich 1800 0    (0) 268 (15) 1532 (85) 
5a 
NAD-restrictedc 600 0    (0) 212 (35) 388 (65) 
NAD-restricted with yeast extractc 300 0    (0) 2   (1) 298 (99) 
NAD-richa, b 500 239  (48) 261 (52) 0   (0) 
9 
NAD-restrictedc 1200 42    (4) 400 (33) 758 (63) 
NAD-restricted with yeast extractc 300 0    (0) 29 (10) 271 (90) 
NAD-richa, b 700 700 (100) 0   (0) 0   (0) 
10 
NAD-restrictedc 100 141   (13) 770 (70) 189 (17) 
NAD-restricted with yeast extractc 300 57   (19) 198 (66) 45 (15) 
NAD-richa, b 600 401   (67) 199 (33) 0   (0) 
a = significant different from NAD-restricted group 
b = significant different from NAD-restricted with yeast extract group 
c = significant different from NAD-rich group 
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Figure 1: Light micrograph of alveolar epithelial cells incubated with an A. pleuropneumoniae 
serotype 9 strain grown on NAD-restricted (a) and NAD-rich (b) media.  A high degree of 
adhesion is observed when bacteria were grown on NAD-restricted media: alveolar epithelial 
cells are surrounded by these bacteria.  Bar = 10 µm. 
 
Influence of culture conditions on expression of capsule 
Bacterial cells of A. pleuropneumoniae serotype 2, 5a and 9 strains were covered with a layer 
of capsular material (Figure 2a and 2b).  The thickest capsular layer (40-100 nm) was seen 
around cells from the serotype 2 and 5a strains grown in NAD-rich conditions (Figure 2a).  
These capsules had a regular, continuous appearance.  The capsule of these strains was 
thinner and more irregular when grown in NAD-restricted conditions (20 to 50 nm) (Figure 2b).  
The serotype 9 strain had an irregular capsule with a thickness between 20 to 80 nm 
irrespective of the growth conditions.  
 
  
 
Figure 2a: Transmission electron micrograph 
of thin sections of A. pleuropneumoniae 
serotype 5a cells grown in NAD-rich 
conditions.  Cells were stabilized with whole-
cell homologous antiserum.  Arrow shows 
capsular material.  Bar = 200 nm. 
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Figure 2b: Transmission electron micrograph of thin sections of A. pleuropneumoniae 
serotype 5a cells grown in NAD-restricted conditions.  Cells were stabilized with whole-cell 
homologous antiserum.  Arrow shows capsular material.  Bar = 200 nm. 
 
 
Influence of culture conditions on expression of fimbriae 
Fimbriae extending outward from the cell walls were demonstrated on all A. 
pleuropneumoniae strains grown on the NAD-restricted medium and on the A. 
pleuropneumoniae serotype 2 strain grown on the NAD-rich medium.  The fimbriae were most 
easily observed when rotary shadowing was used.  They were filamentous, had a length of 
400-800 nm and a width of 5-8 nm (Figure 3).  The density of the fimbriae varied from cell to 
cell but was in general low.  Not all cells in a culture were fimbriated.  Fimbriae as described 
above could not be detected on the serotype 5a, 9 and 10 strains grown on the NAD-rich 
medium. 
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Figure 3:  Transmission electron micrograph of the A. pleuropneumoniae serotype 2 strain 
grown on NAD-restricted medium.  Long and thin filamentous appendages are indicated with 
arrow.  Bar = 200 nm. 
 
Influence of culture conditions on expression of outer membrane proteins 
SDS-PAGE analysis of the sarcosyl-insoluble OMP fraction of A. pleuropneumoniae serotype 
2, 5a, 9 and 10 strains grown on the NAD-rich or on the NAD-restricted medium is shown in 
Figure 4.  In the OMP fraction of the serotype 5a, 9 and 10 strains, a 55 kDa band was 
observed when bacteria were grown in NAD-restricted conditions.  This band was absent or 
much weaker when bacteria were grown in NAD-rich conditions.  The 55 kDa band was 
present in the OMP fraction of the serotype 2 strain under both growth conditions.  
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Figure 4:  Silver-stained SDS-PAGE profiles of outer membrane protein fractions of A. 
pleuropneumoniae strains.  Lanes: 1, serotype 2 strain grown on NAD-rich medium; 2, 
serotype 2 strain grown on NAD-restricted medium; 3, serotype 5a strain grown on NAD-rich 
medium; 4, serotype 5a strain grown on NAD-restricted medium.  Arrows indicate 55 kDa 
band.  The molecular masses are indicated on the right. 
 
N-terminal amino acid sequence analysis 
For the analysis of the N-terminal amino acid sequence of the 55 kDa OMP of the A. 
pleuropneumoniae serotype 5a and 10 strains, twenty-six cycles were run.  For both 
serotypes, the following main sequence was found: Gly-Lys-Asp-Leu-Asn-Val-Phe-Asp-Lys-
Asn-Tyr-Gly-Leu-Leu-Ile-Asn-Gly-Lys-(Gln)-Thr-Gln/Ala-Phe-Arg-Ser-Gly/Asp-Asp.  No 
homology with other protein sequences was found in the databases. 
Effect of pretreatment of bacterial cells with enzymes, heat, sodium metaperiodate, 
tetramethylurea and carbohydrates on adhesion to alveolar epithelial cells 
Results are presented in Table 2.  Treatment of the bacterial cells with enzymes, heat and 
sodium metaperiodate significantly decreased the adhesion of the serotype 2 strain.  
Treatments could be arranged in descending degree of inhibition as follows: combination of 
sodium metaperiodate and pronase, heat, pronase, pepsin, trypsin and sodium 
metaperiodate.  For the serotype 5a strain, single sodium metaperiodate treatment had no 
significant effect on the adhesion.  Treatment of the bacterial cells with enzymes and heat 
significantly decreased the adhesion. The highest inhibition was found with heat and a 
- 58 
 
 
- 38.8 
 
 
- 29 
Experimental studies 
 79
combination of sodium metaperiodate and pronase followed by pronase, pepsin and trypsin.  
For the serotype 9 strain, all treatments significantly inhibited the adherence.  In descending 
order, inhibition was observed with heat, combination of sodium metaperiodate and pronase, 
pronase, pepsin, trypsin and sodium metaperiodate. 
Tetramethylurea or carbohydrate treatment did not reduce the level of adhesion.  Pronase, 
trypsin, TMU and carbohydrate treatment of the bacterial cells did not have any effect on the 
viability.  Treatment of the bacteria with heat, pepsin and sodium metaperiodate resulted in a 
decrease in viability.  
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Table 2. Effect of pretreatment of the bacterial cells with heat, enzymes and sodium metaperiodate on the adhesion of A. pleuropneumoniae strains to alveolar epithelial cells 
Serotype Scores* 
% of alveolar epithelial cells with score 0, 1 or 2 after treatment of bacteria with 
No treatment Pepsin Trypsin Pronase 
Heat 
10 min 
Heat 
20 min 
Heat 
30 min 
Sodium 
metaperiodate 
Sodium 
metaperiodate + 
pronase 
Pronase + sodium 
metaperiodate 
2 
0 0 11 5 20 16 8 6 1 76 9 
1 12 66 69 72 84 88 93 71 24 77 
2 88 23 25 8 0 5 1 28 0 14 
  a a a, b, c, h a, b, c, h, j a, c, h a, b, c, h a a, b, c, d, e, f, g, h, j a, h 
5a 
0 18 38 22 61 54 39 76 0 72 12 
1 50 54 63 39 46 61 24 62 28 57 
2 32 8 15 0 0 0 0 38 0 31 
  a, c a a, b, c, f a, b, c a, c a, b, c, f  a, b, c, f  
9 
0 1 24 7 48 76 68 49 0 54 17 
1 37 58 60 49 24 32 51 51 46 73 
2 62 18 3 3 0 0 0 49 0 10 
  a, h, c a, h a, b, c, h, j a, b, c, d, g, 
h, i, j a, b, c, d, h, j a, b, c, h, j a a, b, c, h, j a, c, h 
* 0: 0 bacteria adhering; 1: 1-20 bacteria adhering; 2: >20 bacteria adhering 
a-j: significant difference with no treatment (a), pepsin (b), trypsin (c), pronase (d), heat 10 min (e), heat 20 min (f), heat 30 min (g), sodium metaperiodate (h), sodium metaperiodate + pronase (i), pronase +  
sodium metaperiodate (j) 
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DISCUSSION 
In previous studies, it has been shown that A. pleuropneumoniae adheres to alveolar 
epithelial cells of experimentally infected pigs (Dom et al., 1994 & 1995).  Most probably, 
adherence of A. pleuropneumoniae to lower respiratory tract epithelial cells constitutes an 
important initial step in pathogenesis.  Therefore, in the present work, porcine alveolar 
epithelial cells were used to study the adhesion of A. pleuropneumoniae.  The alveolar 
epithelial cells were allowed to attach to coverslips whereafter they were fixed with methanol.  
Fixation was used to prevent destruction of the alveolar epithelial cells by the Apx toxins of A. 
pleuropneumoniae (Van de Kerkhof et al., 1996). 
Advantages of using an in vitro system include reproducibility between assays, ease and 
simplicity of experimentation and animal welfare. However, there are also several 
disadvantages.  Surfaces of in vitro cells may present proteins different from in vivo cells, 
especially in terms of distribution and accessibility of the receptors.  Notably, the surfactant 
layer covering the alveolar epithelial cells in vivo is absent in the in vitro adhesion model.  For 
this reason, data obtained in in vitro studies should be confirmed by in vivo studies.  
The functional expression of most bacterial adhesins is not an essential activity for the 
survival of the bacteria.  In fact, most organisms display differences in adhesive qualities 
during growth.  These qualities can be modulated by pH and composition and physical state 
of growth medium (Ofek and Doyle, 1994).  In this study, three growth media were used: a 
medium containing 0.03% NAD which was defined as NAD-rich and two media containing 
0.001% NAD which were defined as NAD-restricted.  For the serotype 5a, 9 and 10 strains, 
we found that growth on the NAD-restricted media resulted in a higher degree of adhesion, 
indicating that adhesins are more expressed.  NAD-restricted conditions may reflect the in 
vivo situation.  It is generally accepted that A. pleuropneumoniae is inhaled and enters the 
lung alveoli directly via the trachea and bronchi.  In the lumen of the lung alveoli, extracellular 
NAD-concentrations most probably are very low, since, based on molecular weight and 
charge, it is unlikely that leakage of NAD out of normal living cells occurs.  The NAD-restricted 
conditions in the lumen of lung alveoli may stimulate the expression of adhesins.  Adhesion of 
A. pleuropneumoniae to alveolar epithelial cells may lead to a local high concentration of Apx 
toxins at the surface of host cells resulting in lysis of these cells (Van de Kerkhof et al., 1996) 
and release of growth components in the environment which may favor multiplication of the 
bacteria in lung tissue.  The adhesion degree of bacteria belonging to the serotypes 5a, 9 and 
10 strains grown for 6 hours on the NAD-rich medium was very low, indicating that adhesins 
were less expressed or less exposed at the bacterial surface.   
Since adhesins should be located at the surface of the bacteria, electron microscopic 
examination and sodium dodecyl sulphate-polyacrylamide gel electrophoresis of outer 
membrane proteins was performed to study the surface components of the bacteria.  For the 
serotype 5a, 9 and 10 strains, production of fimbriae and a 55 kDa outer membrane protein 
were observed when bacteria were grown under NAD-restricted conditions.  These conditions 
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also resulted in highest in vitro adhesion scores to alveolar epithelial cells.  This relationship 
between adherence levels and specific cell surface components might indicate that these 
components could play a role in A. pleuropneumoniae adherence to alveolar epithelial cells.   
In contrast to the A. pleuropneumoniae serotype 5a, 9 and 10 strains, a correlation between 
the growth conditions and the adhesion of the serotype 2 strain was not observed.  This strain 
exhibited a high degree of in vitro adhesion grown under NAD-restricted and NAD-rich 
conditions.  Furthermore, fimbriae and a 55 kDa OMP were expressed under both growth 
conditions.  This confirms that these components could play a role in in vitro adhesion. 
Recently, fimbriae of A. pleuropneumoniae were characterized as type 4 fimbriae (Zhang et 
al., 2000).  Type 4 fimbriae have been described in several other Gram-negative bacteria 
including Haemophilus influenzae, Moraxella bovis, Pasteurella multocida and Pseudomonas 
aeruginosa.  A large number of studies have shown that they mediate attachment of these 
bacteria to epithelial cells in vivo and in vitro (Sato and Okinaga, 1987; Doig et al., 1988; 
Paranchych and Frost, 1988; Starr et al., 1999).  Attempts should be made to try to isolate 
these fimbriae from A. pleuropneumoniae and determine their role in adhesion. 
The outer membrane is an excellent compartment for anchoring and positioning adhesins to 
the outer surface. It has been demonstrated that outer membrane proteins, unrelated to 
fimbriae, can play a role in the adhesion to animal cells.  Examples of such interaction have 
been found in the adhesion reactions of Neisseria gonorrhoeae (Dekker et al., 1990) and 
Pseudomonas aeruginosa (Ramphal et al., 1991).  Recently, a 80 kDa OMP has been 
described that can play a role in the adherence of A. pleuropneumoniae to type III swine lung 
collagen (Enriquez et al., 1999).  In the absence of lesions, collagen is not present on the 
surface of the alveoli, therefore adherence to collagen most probably is not involved in the 
initial adhesion of A. pleuropneumoniae to alveolar epithelial cells in vivo.  
Bacteria were grown for 20 hours on the NAD-restricted medium and only 6 hours on the 
NAD-rich medium.  Since the A. pleuropneumonia strains used in this study were NAD-
dependent, more time was needed for their growth on the NAD-restricted medium.  
Differences in incubation time could result in phenotypic variations of the strains.  However, in 
preliminary studies, no differences in adhesion scores were observed between bacteria grown 
for 6 or 20 hours on the NAD-rich medium (data not shown).  Therefore, most likely, the 
differences in adhesion observed in the present study were due to the altered growth media. 
For many Gram-negative bacteria it has been shown that deprivation of nutrients results in 
the alteration of the protein composition of their outer membrane (Brown and Williams, 1985).  
In the present study, A. pleuropneumoniae serotype 2, 5a, 9 and 10 strains were deprived of 
NAD, resulting in a decreased growth for all strains and the expression of a 55 kDa OMP in 
serotype 5a, 9 and 10 strains.  O’Reilly et al. (1991) demonstrated the expression of OMPs of 
17, 31 and 69 kDa in A. pleuropneumoniae under pyridine nucleotide restricted conditions.  
OMPs in the relative molecular size range of 55 kDa were also described in other studies.  
OMPs of 54 kDa (Niven et al., 1989), 56 kDa (Gonzalez et al., 1990) and 60 kDa 
(Archambault et al., 1999) were induced when cells were grown under iron-restricted 
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conditions.  The 60 kDa OMP was identified as a transferrin binding protein (Gerlach et al., 
1992).  Since the media used in this study were not deprived of iron, most likely the 55 kDa 
OMP does not correspond to an iron-regulated OMP.  Furthermore, our finding that no 
homology in N-terminal amino acid sequence is present in the databases suggests that the 55 
kDa OMP we observed has not yet been described before. 
The capsule of A. pleuropneumoniae is generally regarded as an important virulence factor.  
It protects the pathogen against phagocytosis and lysis by complement (Haesebrouck et al., 
1997).  Capsular polysaccharides are not responsible for adherence to tracheal frozen 
sections, since a higher degree of adhesion was observed with non-capsulated mutant strains 
(Bélanger et al., 1990; Jacques et al., 1991; Rioux et al., 2000).  Furthermore, Bélanger et al. 
(1992, 1994) demonstrated that heavily encapsulated A. pleuropneumoniae strains showed 
no or less affinity for porcine respiratory tract mucus than strains with a thinner capsule.  From 
these studies, it was concluded that the capsule masks surface components, such as LPS, 
responsible for the in vitro adhesion to tracheal frozen sections and mucus.  In the present 
study, the A. pleuropneumoniae serotype 5a strain grown under NAD–restricted conditions 
had a more irregular, thinner capsule and a higher adhesion score.  This could confirm the 
finding that a thinner capsule may expose several adhesins.  However, the serotype 9 strain 
had a thin, irregular capsule irrespective of the growth conditions and a high degree of 
adhesion to alveolar epithelial cells was only observed when the strain was grown on the 
NAD-restricted medium.  This finding indicates that growth conditions, besides affecting the 
adhesion by altering the production of capsular material, may also influence the expression of 
surface antigens that are directly involved in adhesion. 
In the present study, treatment of bacteria with tetramethylurea had no effect on the binding.  
Furthermore, hydrophobicity tests as described by Vercauteren et al. (1993) did not show 
differences in hydrophobicity between bacteria grown under NAD-restricted and NAD-rich 
conditions (data not shown).  This indicates that, although hydrophobic interactions may 
contribute in a subordinate way to the overall adherence mechanism, it is unlikely that 
hydrophobicity per se is a major factor in adherence of A. pleuropneumoniae to alveolar 
epithelial cells.   
Using the in vitro adhesion model, it was noted that the adherence capacity was strongly 
inhibited by treating the bacteria with proteolytic enzymes or heat.  These findings suggest 
that proteins are involved in the adhesion.  Treatment of the bacteria with sodium 
metaperiodate resulted in lower adhesion scores for the serotype 2 and 9 strains but the 
inhibition of adhesion was clearly lower than after treatment with proteolytic enzymes.  
Sodium metaperiodate is known to cleave the C-C bond between neighbouring hydroxyl 
groups of sugar.  This indicates that, besides proteins, carbohydrates could also be involved 
in the adhesion of A. pleuropneumoniae to alveolar epithelial cells. Our finding that inhibition 
of adhesion was very high when bacteria were treated with a combination of sodium 
metaperiodate and pronase also suggests that more than one adhesin is involved. 
Experimental studies 
 84
In conclusion, we present several lines of evidence that more than one adhesin is involved in 
the in vitro adhesion of A. pleuropneumoniae to alveolar epithelial cells and that proteins play 
a major role.  The fimbriae and the 55 kDa OMP, both of protein nature, can be designated as 
candidate-adhesins since bacteria expressing these structures had the highest adhesion 
scores.  The expression of these components was higher under NAD-restricted conditions for 
the A. pleuropneumoniae serotype 5a, 9 and 10 strains, but not for the serotype 2 strain. 
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SUMMARY 
The effect of culture conditions on adhesion of inactivated A. pleuropneumoniae biotype 1-
serotype 2 and 9 strains to alveoli of experimentally inoculated piglets was studied.  Growing 
the bacteria on a NAD-restricted or NAD-rich medium did not influence this adhesion and had 
no effect on the in vitro association of the bacteria with surfactant proteins.  Adhesion scores 
in alveolar epithelial cell cultures were, however, much higher when the serotype 9 strain was 
grown on the NAD-restricted medium.  It is possible that different adhesins are involved in 
colonisation of alveoli of infected pigs.  Association with surfactant might be a first step that 
precedes adhesion to alveolar epithelial cells. 
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INTRODUCTION 
Actinobacillus pleuropneumoniae (A. pleuropneumoniae) is a Gram-negative bacterium 
causing contagious pleuropneumonia in pigs.  Based on NAD requirements, A. 
pleuropneumoniae can be divided into biotype 1 strains, which are NAD-dependent, and 
biotype 2 strains, which are NAD-independent.  So far 15 serotypes have been described 
(Blackall et al., 2002).   
In previous studies it was shown that adhesion of A. pleuropneumoniae to alveoli is an 
important first step in the pathogenesis of porcine pleuropneumonia (Dom et al., 1994a&b).  
The adhesion was further characterized in alveolar epithelial cell cultures (Van Overbeke et 
al., 2002).  For most A. pleuropneumoniae strains tested, it was shown that bacterial growth 
conditions influence in vitro adhesion to alveolar epithelial cells.  Growth of A. 
pleuropneumoniae biotype 1-serotype 5a, 9 and 10 strains under NAD-restricted conditions 
resulted in more bacteria adhering to alveolar epithelial cells, indicating that a higher 
percentage of the bacterial population expresses adhesins under these conditions.  In vitro 
however, cells may present proteins on their surface different from in vivo cells, especially in 
terms of distribution and accessibility of receptors.  Moreover, the surfactant layer covering 
the alveolar epithelial cells in vivo may mask certain receptors on the cell surface.  It has been 
reported that lipopolysaccharides of several bacteria including Salmonella serotype Typhi, 
Klebsiella pneumoniae, Serratia marcescens and Pseudomonas aeruginosa interact with 
surfactant (Brogden et al., 1986).  
It was the aim of the present studies to determine if bacterial growth conditions that influence 
in vitro adhesion to porcine alveolar epithelial cells, also influence adhesion of A. 
pleuropneumoniae to porcine alveolar epithelial cells in vivo.   
 
MATERIALS AND METHODS 
Strains and culture conditions 
Two A. pleuropneumoniae strains belonging to serotype 2 (strain 266/7656) and 9 (strain CVI 
13261) and one Escherichia coli strain (32KH85) were used in this study.  Stock suspensions 
were stored at -70°C in RPMI 1640 medium supplemented with 10% non-essential amino 
acids (Gibco Europe, Merelbeke, Belgium), 10% glutamine, 10% foetal calf serum (FCS) and 
1% sodium pyruvate (Gibco) (leukocyte medium).  The A. pleuropneumoniae bacteria were 
grown on Columbia agar supplemented with 1% horse serum and 0.001% NAD for 20 hours 
at 37°C (NAD-restricted medium) or on Columbia agar supplemented with 3% horse serum, 
0.03% NAD and 5% yeast-extract for 6 hours at 37°C (NAD-rich medium).  Previous studies 
demonstrated that adhesion of the serotype 9 strain to alveolar epithelial cell cultures is much 
higher when bacteria are grown in the NAD-restricted medium.  In vitro adhesion of the 
serotype 2 strain to alveolar epithelial cell cultures is not influenced by these culture 
Experimental studies 
 92
conditions (Van Overbeke et al., 2002).  All incubations were done in an atmosphere with 5% 
CO2. The E. coli strain was grown on Mc Conkey agar for 20 hours at 37°C.  Then, bacteria 
were harvested in phosphate buffered saline solution (PBSS), washed once and resuspended 
in PBSS at a concentration of 109 colony forming units/ml (cfu/ml).  To prevent in vivo 
expression of adhesins, bacteria were inactivated with UV before they were used in the 
experiments.  This suspension was used as inoculum.  Inactivation was checked by plating 
the bacterial suspensions onto Columbia agar supplemented with 5% bovine blood.   
 
In vivo adhesion of A. pleuropneumoniae to alveolar epithelial cells of pigs 
Twenty-seven three-week old Caesarean derived and colostrum deprived pigs were used.  
They were kept in isolation to prevent cross infections with other bacteria or viruses. 
At the age of 3 weeks, pigs were anaesthetized with 2.2 mg/kg tiletamine and 2.2 mg/kg 
zolazepam (Zoletil 100, Virbac, Louvain La Neuve, Belgium) and 4.4 mg/kg xylazin (Xyl-M 
2%, VMD, Arendonk, Belgium).  They were intubated and endobronchially inoculated using 
an endoscope with 1 ml inoculum in the right lung and 1 ml inoculum in the left lung: 8 pigs 
were inoculated with the A. pleuropneumoniae serotype 9 strain grown on the NAD-rich 
medium, 5 pigs with the A. pleuropneumoniae serotype 9 strain grown on the NAD-restricted 
medium, 6 pigs with the A. pleuropneumoniae serotype 2 strain grown on the NAD-rich 
medium, 6 pigs with the A. pleuropneumoniae serotype 2 strain grown on the NAD-restricted 
medium and 2 pigs with109 CFU of the E. coli strain.  The pigs were kept asleep until they 
were euthanized at 30 minutes post-inoculation.  The right and left lung were separated and 5 
samples of the inoculation sites of each lung were taken for histological examination. 
The samples were processed for paraffin sectioning according to standard procedures.  
Sections were stained with Giemsa.  The percentage of bacterial adherence was determined 
by lightmicroscopical examination of the sections.  For each lung, the number of adhering 
bacteria was counted on a total of at least 500 observed bacteria (Dom et al., 1994b). 
 
Interaction of A. pleuropneumoniae with surfactant proteins 
Pig-derived lung surfactant (Curosurf, Serono Benelux, Den Haag, The Netherlands), 
consisting of approximately 99% polar lipids (mainly phospholipids) and 1% hydrophobic, low 
molecular weight proteins (surfactant-associated proteins B and C) was used.  The 
surfactant-associated proteins were biotinylated with a protein biotinylation kit (Amersham 
international, Buckinghamshire, UK). 
One ml of the inactivated A. pleuropneumoniae biotype 1-serotype 2 and 9 strains grown on 
the NAD-rich and the NAD-restricted medium was centrifuged at 400 x g for 10 minutes.  The 
supernatant was discarded and different amounts (80 µg, 40 µg, 20 µg, 10 µg, 5 µg, 2.5 µg or 
1.25 µg) of biotinylated surfactant proteins were added to the pellet of bacteria.  The mixture 
was incubated at 37°C for 1 hour.  Thereafter, bacteria were washed twice with PBSS and 
resuspended in 50 µl of a 1:50 dilution of streptavidine-fluorescein isothiocyanate 
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(streptavidine-FITC) in PBSS.  After another hour of incubation at 37°C, bacteria were 
washed twice with PBSS.  Finally, samples were examined with a fluorescence microscope 
(Leica DM RBE, Brussel, Belgium).   
Controls consisted of A. pleuropneumoniae biotype 1-serotype 2 and 9 strains grown on the 
NAD-rich and the NAD-restricted medium incubated with streptavidine-FITC. 
 
RESULTS 
In vivo adhesion of A. pleuropneumoniae to lung alveolar epithelial cells 
A. pleuropneumoniae serotype 2 and 9 strains grown on the NAD-restricted or NAD-rich 
media were able to adhere to alveolar cells.  The mean percentage of bacteria adhering to the 
alveolar epithelial cells was 72% and 66% for the serotype 9 strain grown on the NAD-rich 
medium or the NAD-restricted medium, respectively.  For the serotype 2 strain, 59% of the 
bacteria grown on the NAD-rich medium and 77% of the bacteria grown on the NAD-restricted 
medium were found in association with alveoli. 
Adhesion was not observed in pigs inoculated with the E. coli strain. 
 
Interaction of A. pleuropneumoniae with surfactant proteins 
Fluorescence was not detected in controls consisting of the A. pleuropneumoniae biotype 1-
serotype 2 and 9 strains incubated with streptavidine-FITC. 
Incubation of the A. pleuropneumoniae biotype 1-serotype 2 and 9 strains with biotinylated 
surfactant and streptavidine-FITC resulted in a clear fluorescence, indicating that surfactant 
associated proteins bound to the bacteria.  The surfactant proteins bound to the serotype 2 
and 9 strains grown on the NAD-restricted or NAD-rich media.  The fluorescence decreased 
when lower concentrations of biotinylated surfactant proteins were used.   
DISCUSSION 
Intranasal inoculation or aerosol exposure closely resembles the natural infection route of A. 
pleuropneumoniae.  These methods are difficult to standardize, however, because coughing, 
sneezing, swallowing, breathing and mucociliary clearance can reduce the number of bacteria 
that reach the alveolar region. In the present study, the bacteria were inoculated 
endobronchially using an endoscope. Advantages of this approach are that it delivers an 
exact number of bacteria in the bronchi and it delivers the bacteria at a choosen place in the 
lung.  This allows standardization of the experimental inoculations. Pigs were anaesthetized 
before the inoculation and were kept asleep until they were euthanized.  Coughing, sneezing 
and swallowing was hereby avoided.  It is to be expected that a certain amount of bacteria are 
eliminated by breathing.  However, this reduction of the number of bacteria is probably 
equivalent for the different serotypes.      
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In the present studies, A. pleuropneumoniae serotype 2 and 9 strains grown on the NAD-
restricted or NAD-rich media were able to adhere to lung alveoli of experimentally inoculated 
pigs.  For the serotype 9 strain, this is in contrast with the results of previously described in 
vitro adhesion tests (Van Overbeke et al., 2002).  For this strain, growth on NAD restricted 
media resulted in significantly more bacteria adhering to alveolar epithelial cells in vitro than 
when bacteria were grown on NAD rich media.  The reason for this difference between in vivo 
and in vitro is not clear.  Surfaces of in vitro cells however, may present proteins different from 
in vivo cells (Arp, 1988).  Moreover, the surfactant layer covering the alveolar epithelial cells 
in vivo is absent when performing in vitro adhesion studies.  Our finding that bacterial growth 
conditions did not influence the interactions of A. pleuropneumoniae with surfactant proteins 
also indicates that the adhesion of A. pleuropneumoniae to alveoli of pigs observed in the 
present studies, might be due to interactions with surfactant.   
The E. coli strain did not adhere to alveolar epithelial cells.  This suggests that the adhesion 
observed with the A. pleuropneumoniae strains was a specific interaction.   
It remains to be determined which bacterial antigens are involved in binding of A. 
pleuropneumoniae to surfactant proteins.  Several putative adhesins have already been 
described, including lipopolysaccharides that seem to be responsible for in vitro adhesion to 
porcine tracheal rings (Bélanger et al., 1990) and mucus (Bélanger et al., 1992&1994), a 80 
kDa outer membrane protein that could play a role in the adherence of A. pleuropneumoniae 
to type III swine-lung collagen (Enriquez et al., 1999), a 55 kDa outer membrane protein and 
type IV fimbriae (Van Overbeke et al., 2002; Boekema et al.,2003).  It is unlikely that the latter 
two antigens are responsible for binding of surfactant proteins since in the serotype 9 strain 
used in the present studies they are mainly expressed when bacteria are grown on a NAD 
restricted medium (Van Overbeke et al., 2002). 
It is possible that more than one adhesin is involved in adhesion of A. pleuropneumoniae to 
alveoli of infected pigs.  This already has been shown for related bacteria causing respiratory 
tract infections such as Mannheimia haemolytica (Brogden et al., 1989) and Haemophilus 
influenzae (Read et al., 1992).  Association of A. pleuropneumoniae with surfactant might be 
a first step in colonization of alveoli followed by adhesion to the plasma membrane of alveolar 
epithelial cells.  Such a two step adhesion has already been demonstrated for other bacteria 
including enterohemorrhagic Escherichia coli (Hicks et al., 1998).   
To establish the role of different antigens in colonisation of alveoli further in vivo and in vitro 
studies with mutant strains lacking the capacity to express these candidate adhesins, are 
required. 
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SUMMARY 
The efficacy of two bacterins containing an Actinobacillus pleuropneumoniae serotype 10 
strain was evaluated.  The bacterial cells constituting bacterin 1 and 2 were grown under 
NAD-rich (low adherence capacitiy to alveolar epithelial cell cultures) and NAD-restricted 
(high adherence capacity to alveolar epithelial cell cultures) conditions, respectively.  Ten pigs 
were vaccinated twice with the bacterin 1 and 9 pigs with the bacterin 2.  Ten control animals 
were injected twice with a saline solution.  Three weeks after the second vaccination, all pigs 
were endobronchially inoculated with 106.5 colony-forming units (CFU) of an A. 
pleuropneumoniae serotype 10 strain.  In the bacterin 1 and 2 group, three and two pigs died 
after inoculation, respectively.  Only two pigs of the control group survived challenge.  
Surviving pigs were killed at 7 days after challenge.  The percentage of pigs with severe lung 
lesions (>10% of the lung affected) was 100% in the control group, 70% in the bacterin 1 
group and 22% in the bacterin 2 group.  A. pleuropneumoniae was isolated from the lungs of 
all animals.  The mean bacterial titres of the caudal lung lobes were 7.0x106 CFU/g in the 
control group, 6.3x105 CFU/g in the bacterin 1 group and 1.3x106 CFU/g in the bacterin 2 
group.  It was concluded that both bacterins induced partial protection against severe 
challenge.  Furthermore, there are indications that the bacterin 2, containing A. 
pleuropneumoniae bacteria grown under conditions resulting in high in vitro adhesion, 
induced better protection than the bacterin 1.   
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INTRODUCTION 
Actinobacillus pleuropneumoniae causes porcine contagious pleuropneumonia, which is 
distributed world wide and results in serious losses in the pig rearing industry.  It also causes 
severe animal suffering.  Infected pigs may develop acute hemorrhagic necrotizing 
pneumonia and fibrinous pleuritis or chronic localized lung lesions and adhesive pleuritis 
(Taylor, 1999).  To control outbreaks of this disease, vaccination may be useful.  Vaccines 
containing the A. pleuropneumoniae Apx toxins have become commercially available and in 
previous studies, partial protection against endobronchial challenge in animals vaccinated 
with these vaccines was demonstrated (Chiers et al., 1998; Van Overbeke et al., 2001).  Field 
trials carried out in France (Pommier et al., 1996), the Netherlands (Valks et al., 1996), Italy 
(Martelli et al., 1996), Spain (López et al., 1998) and Norway (Lium et al., 1998) confirmed 
that vaccination with Apx-containing vaccines can result in reduction of clinical symptoms and 
lung lesions of acute and chronic pleuropneumonia and improvement of performance (growth, 
feed conversion, cost of medication).   
Apx toxins are not the only antigens that could play a role in protection against porcine 
pleuropneumonia.  Capsular antigens, cell wall lipopolysaccharides, outer membrane 
proteins, fimbriae, transferrin binding proteins and adhesins also are important virulence 
factors (Haesebrouck et al., 1997).   
Adherence to host tissue is generally regarded as an important prerequisite for colonization 
and virulence manifestation of bacteria (Ofek and Beachy, 1980).   
In previous studies, it was shown that A. pleuropneumoniae adheres to alveolar epithelial 
cells of experimentally infected pigs (Dom et al., 1994a; 1995).  It has also been shown that 
A. pleuropneumoniae adheres to porcine tracheal rings maintained in culture (Bélanger et al., 
1990), to porcine frozen tracheal and lung sections Jacques et al., 1991), to erythrocytes from 
various animal species (Jacques et al., 1988), to porcine tonsillar epithelial cells (Chiers et al., 
1999), to swine buccal epithelial cells (Hamer et al., 1999), to type III swine-lung collagen  
(Enriqueze et al., 1999) and to a culture of alveolar epithelial cells (Van Overbeke et al., 
2002).  In the latter study, it has been demonstrated that adhesive qualities of A. 
pleuropneumoniae to alveolar epithelial cells were influenced by growth conditions.   Growth 
of A. pleuropneumoniae under NAD-restricted conditions results in more bacteria adhering to 
alveolar epithelial cells, indicating that a higher percentage of the bacterial population 
expresses adhesines under these conditions. The high adhesion scores of bacteria grown 
under NAD-restricted conditions have been related to expression of fimbriae and a 55 kDa 
outer membrane protein.   
The present study was undertaken to determine if pigs, vaccinated with a bacterin consisting 
of bacteria grown under NAD-restricted conditions (high in vitro adherence capacity), were 
better protected or not against an A. pleuropneumoniae infection than pigs vaccinated with a 
bacterin consisting of bacteria grown under NAD-rich conditions (low in vitro adherence 
capacitiy).  
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MATERIALS AND METHODS 
Challenge strain 
An A. pleuropneumoniae serotype 10 reference strain D13039 was used.  Bacteria were 
grown for 6 hours (log phase of growth) on Columbia agar (Columbia Agar Base, Lab M, 
Bury, Great Britain) supplemented with 3% horse serum, 0.03% NAD (Sigma Chemical Co, St 
Louis, Mo, USA), and 5% yeast extract at 37°C in a humid atmosphere with 5% CO2.  
Bacteria were harvested in phosphate-buffered saline solution (PBSS, pH 7.3), centrifuged at 
400 x g for 20 minutes, and suspended in RPMI (Roswell Park Memorial Institute) 1640 
supplemented with 10% non-essential amino acids, 10% glutamine, 10% fetal calf serum, and 
1% sodium pyruvate (Dom et al., 1994a).  The suspension was checked for purity and the 
number of colony-forming units (CFU) was determined by plating tenfold dilutions on 
Columbia agar supplemented with 3% horse serum, 0.03% NAD, and 5% yeast extract.  
Bacterial suspensions were stored overnight at 4°C.  The next day, they were used in the 
challenge experiments.   
Pigs 
Twenty-nine conventional pigs were obtained by using a medicated segregated early weaning 
programme (Chiers et al., 1998).  They were weaned at 18 days of age and kept in isolation 
until used in the experiments. 
Vaccine 
Two bacterins were used.  Bacterin 1 contained A. pleuropneumoniae serotype 10 strain 
D13039 grown on Columbia agar supplemented with 3% horse serum, 0.03% NAD and 5% 
yeast-extract for 6 hours at 37°C (NAD-rich medium).  Bacterin 2 contained the A. 
pleuropneumoniae serotype 10 strain D13039 grown on Columbia agar supplemented with 
1% horse serum and 0.001% NAD for 20 hours at 37°C (NAD-restricted medium).   
The bacteria were harvested from the agar in PBSS, washed once with PBSS and 
resuspended in PBSS to achieve a suspension of 109 CFU/ml.  Bacteria in each suspension 
were inactivated by UV-light.  This inactivation procedure does not affect in vitro adhesion to 
alveolar epithelial cell cultures (data not shown).  After inactivation, the bacterins were 
emulsified in an equal volume of a mineral oil adjuvans (De Herdt et al., 1999). 
Experimental design 
At the age of 20 and 23 weeks, pigs were intramuscularly injected: 10 pigs with 2 ml of the 
bacterin 1, 9 pigs with 2 ml of the bacterin 2 and 10 pigs with 2 ml of a saline solution.  Three 
weeks after the second injection, all pigs were experimentally infected.  The pigs were 
anaesthetized with Zoletil 100 (2.2 mg/kg tiletamine and 2.2 mg/kg zolazepam, Virbac, 
Louvain La Neuve, Belgium) and Xyl-M 2% (4.4 mg/kg xylazin, VMD, Arendonk, Belgium).  
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They were inoculated endobronchially with 106.5 CFU of the challenge strain in 5 ml inoculum 
(Van Overbeke et al., 2001).  All pigs were examined clinically.  Pigs that died were autopsied 
immediately; those that survived the challenge were killed 7 days after inoculation.  At 
necropsy, the lungs were examined macroscopically and the percentage of affected lung 
tissue was determined.  For this purpose, a diagram was used that divides the lung into 74 
equal triangles (Hannan et al., 1982).  The percentage of affected lung tissue was determined 
by summing up the triangles showing pneumonia and/or pleuritis divided by 74.  Samples 
from lungs and tracheobronchial lymph nodes, were taken for bacteriological examination.  
Sera were collected before the first and the second vaccination and before the challenge. 
Clinical examination 
The pigs were examined for signs of pneumonia, characterized by increased respiratory rate 
(>40 inspirations/min), dyspnoea, sneezing, coughing, and the presence of a bloody foam on 
mouth and/or nostrils.  Rectal temperature was measured 1 day before challenge inoculation, 
just before inoculation, and during the 7 days after inoculation.  Other indications of infection 
were vomiting and a depressed appearance. 
Bacteriological examination 
Twenty per cent (w/v) suspensions of the right and the left caudal lung lobes were made in 
PBSS.  The samples were tested for the presence of A. pleuropneumoniae by  inoculating the 
suspensions onto Columbia agar supplemented with 5% bovine blood with a Staphylococcus 
intermedius streak.  The number of cfu was determined by plating tenfold dilutions of the 
suspensions on Columbia agar supplemented with 3% equine serum, 0.03% NAD and 5% 
yeast extract.  Samples from tracheobronchial lymph nodes were tested for the presence of 
A. pleuropneumoniae by making an incision in these tissues and taking a sample with an 
inoculation loop.  These samples were inoculated onto Columbia agar supplemented with 5% 
bovine blood with a Staphylococcus intermedius streak.  Identification of A. 
pleuropneumoniae was based on the CAMP reaction and the inhanced growth around the 
Staphylococcus intermedius streak. 
Serology 
All pig sera were tested for presence of ApxI neutralizing antibodies using a bioassay based 
on neutral red uptake by viable pulmonary alveolar macrophages, as described previously 
(Dom et al., 1994b) and for the presence of antibodies against cell-surface antigens of A. 
pleuropneumoniae serotype 10 strain D13039 grown on the NAD-rich and NAD-restricted 
media using an ELISA assay.  The bacteria were harvested from the agar in PBSS, washed 
once with PBSS and resuspended in PBSS to achieve a suspension of 109 CFU/ml.  After 
inactivation of the bacteria by UV-light, the suspension was centrifuged and resuspended in 
coatingbuffer (0.05M carbonate-bicarbonate buffer, pH 9.6) to achieve a suspension of 107
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CFU/ml.  Wells of a microtiter plate (Nunc-Immuno Plate MaxiSorp, Gibco, Ghent, Belgium) 
were coated with 150 µl coatingbuffer containing the bacteria and incubated overnight at 4°C.  
The next day, plates were washed four times with PBSS containing 0.05% Tween-20 (VWR 
International, Leuven, Belgium) (PBSS-T, pH 7.2). Non-specific binding was blocked by 
incubating the plates with 5% (w/v) glycine (VWR International) in PBSS-T.  Plates were 
washed twice with PBSS-T, and were incubated with 1/200 dilution of sera.  Bound antibodies 
were detected using 1/800 diluted peroxidase-conjugated rabbit anti-pig immunoglobulin 
serum (Sigma).  Aminosalicylic acid and H2O2 (Sigma) were used as enzyme substrate.  
Reactions were read at 405 nm using a microELISA reader (Titertek Multiscan Plus).  The OD 
values of wells devoided of sera served as background values. 
Sera collected at the time of challenge were also tested for the presence of antibodies against 
a 55 kDa outer membrane protein of A. pleuropneumoniae serotype 10 strain D13039.  
Sarcosyl-insoluble outer membrane proteins of the A. pleuropneumoniae serotype 10 strain 
grown on the NAD-restricted medium were prepared as previously described (Van Overbeke 
et al., 2002).  The outer membrane proteins were separated using discontinuous sodium 
dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE).  Electrophoresis 
experiments were performed with a 4.5% stacking gel and a 12% running gel.  The antigen 
preparation was mixed with equal volumes of solubilization buffer [4% (w/v) of SDS, 10% (v/v) 
2-mercapto ethanol, 17.4% (v/v) glycerol and 0.01% bromophenol blue in 0.06M Tris HCl (pH 
6.8)] and boiled for 5 minutes prior to electrophoresis.  After electrophoresis, antigens were  
electroblotted onto an immobilon polyvinylidene difluoride membrane (Millipore, Bedford, 
Mass., USA) using a semi-dry blotting system (190 mA, 1h, Bio-Rad Laboratories, Richmond, 
USA).  Blotted proteins were subsequently probed with 1/100 diluted pig sera and 1/800 
diluted anti-pig IgG serum conjugated with peroxidase (Sigma).  Recognised antigens were 
visualised with chloronaftol and H2O2.  To stop the reactions, the strips were washed three 
times in distilled water.  A standard solution of prestained proteins with a molecular range 
from 14.2-97 kDa was used as a marker (Sigma, SDS-6B). 
Statistical analysis 
Statistical analysis was performed on the following variables: percentage of mortality, 
percentage of animals with fever, percentage of animals with dyspnoea, percentage of pigs 
with severe lung lesions (>10% of the lung affected), mean percentage of affected lung tissue 
and logarithmic mean of bacterial titre in caudal lung lobes.   
A logistic regression analysis was used to compare the percentage of mortality, percentage of 
animals with fever, percentage of animals with dyspnoea, mean percentage of affected lung 
tissue and percentage of pigs with severe lung lesions (>10% of the lung affected).  A 
Wilcoxon signed rank test was used to compare the log mean bacterial titres in caudal lung 
lobes between groups. 
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RESULTS 
Results are summarized in Table 1. 
Clinical examination 
None of the animals showed disease signs before challenge and at the time of challenge.   
In the control group (n=10), 6 pigs died and 2 animals were euthanised within 48 h after 
inoculation.  The two remaining pigs showed dyspnoea and fever on day 1.  Thereafter, one 
pig had dyspnoea and occasional coughing for another day and fever (>40°C) for 6 days.  
The other pig had an increased respiratory rate during 4 days after challenge.   
In the bacterin 1 group (n=10), one pig was euthanised one day after challenge and 2 other 
animals were euthanised on day 2.  Respiratory signs (dyspnoea, increased respiratory rate 
or coughing) and fever could be detected in five animals.  The duration of these signs varied 
between one day and 6 days.  Two pigs had only an increased respiratory rate during 2 and 4 
days.  Three of the animals were depressed for 1 to 2 days. 
In the bacterin 2 group (n=9), two pigs showed very severe symptoms and were euthanised.  
Four animals developed respiratory signs and fever.  Duration of these symptoms varied 
between 1 and 7 days.  Two animals had fever without respiratory symptoms.  One pig 
showed an increased respiratory rate for 1 day.  Two animals were depressed for 2 days. 
A significant difference (p<0.05) was found for the percentage of mortality between the control 
group and the bacterin 1 group (low adhesin expression) (p=0.033) and bacterin 2 (high 
adhesin expression) group (p=0.009).  There was also a significant difference for the 
percentage of animals with dyspnoea between the control group and the bacterin 2 (high 
adhesin expression) group (p=0.049). 
Necropsy  findings 
In all animals lung lesions, when present, were characterized by a haemorrhagic necrotizing 
pneumonia and fibrinous pleuritis .   
All animals of the control group had severe lung lesions (>10% of the lungs affected).  The 
mean percentage of affected lung tissue was 56% (variation 16-100%).   
In the bacterin 1 group, seven animals had severe lung lesions.  One animal had very mild 
lung lesions and 2 animals had no lung lesions.  The percentage of affected lung tissue varied 
between 0% and 57% (mean: 25%).   
In the bacterin 2 group, two animals had severe lung lesions.  Six animals had very mild lung 
lesions and 1 animal had no lung lesions.  The percentage of affected lung tissue varied 
between 0% and 88% (mean: 16%).   
A significant difference was found for the percentage of animals with severe lung lesions 
between the bacterin 2 (high adhesin expression) group and the control group (p=0.007) and 
between the bacterin 2 (high adhesin expression) group and the bacterin 1 (low adhesin 
expression) group (p=0.047).  The mean percentage of affected lung tissue differed 
significantly between both bacterin groups and the control group (p<0.001) and between the 
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bacterin 2 (high adhesin expression) group and the bacterin 1 (low adhesin expression) group 
(p<0.001). 
Bacteriology 
The results are summarized in Table 1.   
In the control pigs, A. pleuropneumoniae was isolated from all lung lobes.  The number of 
CFU/gram lung tissue of the caudal lobes varied between 3.0 x 105 and 2.8 x 108, with a 
logarithmic mean of 7.0 x 106.  The challenge strain was isolated from  the tracheobronchial 
lymphnodes of 8 pigs.   
In the bacterin 1 group, A. pleuropneumoniae was isolated from all lung lobes.  The number 
of CFU/gram lung tissue of the caudal lobes varied between 5.2 x 102 and 1.8 x 108, with a 
logarithmic mean of 6.3 x 105. A. pleuropneumoniae was isolated from the tracheobronchial 
lymphnodes of 1 pig.  
In the bacterin 2 group, A. pleuropneumoniae was isolated from all lung lobes.  The number 
of CFU/gram lung tissue of the caudal lobes varied between 3.6 x 104 and 9.4 x 107, with a 
logarithmic mean of 1.3 x 106. A. pleuropneumoniae was isolated from the tracheobronchial 
lymphnodes of 2 pigs.  
No significant difference (p<0.05) was found between the logarithmic mean of bacterial titres 
in the caudal lung lobes for the different groups. 
Serology 
In none of the animals, neutralizing antibodies against the Apx I toxin were detected.   
Antibodies against cell-surface antigens were detected in both bacterin groups.  OD values 
were in the same range for both antigen preparations. At the time of first vaccination, a mean 
OD value (standard deviation) was found of 0.132  (0.050) for the bacterin 1 group, 0.121 
(0.059) for the bacterin 2 group and 0.124 (0.041) for the control group.  At the time of second 
vaccination, a mean OD value (standard deviation) was found of 0.410 (0.103) for the 
bacterin 1 group, 0.408 (0.138) for the bacterin 2 group and 0.113 (0.23) for the control group.  
At the time of challenge, a mean OD value (standard deviation) was found of 0.454 (0.103) for 
the bacterin 1 group, 0.509 (0.161) for the bacterin 2 group and 0.132 (0.029) for the control 
group.  The background OD values were in the same range as the OD values of the control 
group.   
Antibodies against a 55 kDa outer membrane protein could not be detected in the sera 
collected at time of challenge.   
Serology 
In none of the animals, neutralizing antibodies against the Apx I toxin were detected.   
Antibodies against cell-surface antigens were detected in both bacterin groups.  OD values 
were in the same range for both antigen preparations. At the time of first vaccination, a mean 
OD value (standard deviation) was found of 0.132 (0.050) for the bacterin 1 group, 0.121 
(0.059) for the bacterin 2 group and 0.124 (0.041) for the control group.  At the time of second 
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vaccination, a mean OD value (standard deviation) was found of 0.410 (0.103) for the 
bacterin 1 group, 0.408 (0.138) for the bacterin 2 group and 0.113 (0.23) for the control group.  
At the time of challenge, a mean OD value (standard deviation) was found of 0.454 (0.103) for 
the bacterin 1 group, 0.509 (0.161) for the bacterin 2 group and 0.132 (0.029) for the control 
group.  The background OD values were in the same range as the OD values of the control 
group.   
Antibodies against a 55 kDa outer membrane protein could not be detected in the sera 
collected at time of challenge. 
 
 
 
 
 
Table 1: Results of endobronchial challenge with A. pleuropneumoniae serotype 10 in pigs 
vaccinated with bacterin 1 and bacterin 2 and in non-vaccinated control pigs 
 
Bacterin 1 (low 
adhesin expression) 
(n=10) 
Bacterin 2 (high 
adhesin expression) 
(n=9) 
Controls (n=10) 
% mortality  30 (a) 22 (a) 80 (b, c) 
% animals with 
dyspnoea1 
71 38 (a) 100 (c) 
% animals with fever1; 2 71 88 100 
% animals with severe 
lung lesions (>10% of 
the lung affected) 
70 (c) 22 (a, b) 100 (c) 
mean % affected lung 
tissue 
25 (a, c) 16 (a, b) 56 (b, c) 
Logaritmic mean 
bacterial titre in caudal 
lung lobes in CFU/ml  
(standard deviation) 
6.3 x 105 
(± 4.3 x 101) 
1.3 x 106 
(± 1.1 x 101) 
7 x 106 
(± 8.3 x 100) 
 
1. only those pigs that survived challenge 
2. fever is defined as a body temperature of ≥ 40°C 
 (a) = significant difference with control group 
(b) = significant difference with bacterin 1 (NAD-rich) group 
(c) = significant difference with bacterin 2 (NAD-restricted) group 
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DISCUSSION 
Intranasal inoculation or aerosol exposure closely resemble the natural infection route of A. 
pleuropneumoniae.  However, these methods are difficult to standardize because coughing, 
sneezing, swallowing, breathing and mucociliary clearance can reduce the number of bacteria 
that reach the alveolar region.  In the present study, an endobronchial challenge model was 
used.  An advantage of this model is that it delivers an exact number of bacteria into the 
bronchi, allowing standardization of experimental infections.  Furthermore, this method allows 
us to bring the bacteria directly close to the multiplication site of A. pleuropneumoniae, 
namely the alveoli and bronchioli (Haesebrouck et al., 1997).  A possible disadvantage is that 
the challenge strain is applicated not all over the lung but is given more focal.  Endobronchial 
challenge is therefore more likely to break through low level immunity in the respiratory tract 
than a more natural challenge route.   
Eight of the 10 control animals died after infection.  This demonstrates that a severe 
challenge model was used. 
There was a significant difference in the percentage of mortality and the mean percentage of 
affected lung tissue between the control group and the bacterin groups.  This indicates that 
both bacterins induced partial protection against severe challenge. 
The percentage of animals with severe lung lesions and the mean percentage of affected lung 
tissue were significant lower in the bacterin 2 (high adhesin expression) group than in the 
bacterin 1 (low adhesin expression) group.  Furthermore, there was also a significant 
difference for the percentage of animals with dyspnoea between the control group and the 
bacterin 2 (high adhesin expression) group.  This could indicate that the bacterin 2, i.e. a 
bacterin containing bacteria grown under NAD-restricted conditions resulting in high in vitro 
adhesion to a culture of alveolar epithelial cells, provides better protection.  Further studies 
are necessary to determine which antigens could be involved. 
Bacterins were based on UV-inactivated and washed A. pleuropneumoniae bacteria.  In sera 
of vaccinated animals, antibodies against the Apx I toxin were not found, suggesting that this 
toxin is not cell-associated but is only secreted into the culture medium.  This is also 
mentioned by Frey and Nicolet (1991), but is in contrast with the reports by Fedorka-Cray 
(1989; 1993). 
In previous studies, it was demonstrated that a 55 kDa outer membrane protein was 
expressed by the serotype 10 strain used in the present studies when bacteria were grown 
under NAD-restricted conditions (Van Overbeke et al., 2002).  However, antibodies against 
this protein were not detected by Western blot analysis in sera of vaccinated animals at the 
time of challenge.  The reason for this finding is not clear. It is possible that the 
immunogenicity of the 55 kDa outer membrane protein is low or that antibodies do not 
recognise the denaturated protein used in Western Blot analysis.  Antibody reactions 
occurred between other outer membrane protein components and sera of vaccinated animals 
at the time of challenge (data not shown).  However, there was no marked difference between 
the groups. 
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In the present studies, animals were only challenged with a serotype 10 strain.  It has been 
shown that whole-cell bacterins based on bacteria grown in NAD-rich conditions generally do 
not confer protection against challenge with heterologous serotypes (Fenwick and Henry, 
1994). An explanation for the limited protection might be the absence of secreted and certain 
bacteria-associated virulence factors in these bacterins.  Further challenge studies with 
heterologous serotypes are necessary to determine if a vaccine containing bacteria grown in 
NAD-restricted conditions induces protection against other serotypes. 
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GENERAL DISCUSSION 
A. pleuropneumoniae causes severe losses in the pig rearing industry (Nicolet et al., 1992).  
Although the disease can be controlled by antimicrobial agents, the use of these products has 
several disadvantages including induction of acquired resistance in pathogenic bacteria and 
bacteria belonging to the normal flora of pigs.  The latter bacteria may act as a reservoir of 
antimicrobial resistance genes for bacteria that cause disease in humans or animals.  
Excessive use of antimicrobials may also result in the presence of residues in meat.  
Therefore, prevention is a better option for the control of the disease.  Vaccines could be very 
useful to control porcine pleuropneumonia.  Rational design of effective antibacterial 
vaccines, however, requires knowledge of the virulence factors of the bacterium and the 
pathogenesis of the disease.  Pathogenesis of porcine pleuropneumonia is very complex and 
several virulence factors have been described.  Some of these virulence factors, such as the 
Apx toxins, have been extensively studied.  Virulence attributes involved in lung colonisation 
are, however, less understood.  The need for research in the first steps of pathogenesis 
provided the main rationale for this thesis. 
 
Recovery from naturally acquired infection with A. pleuropneumoniae provides solid, serotype 
cross-protective immunity.  Evidence from field and experimental studies indicates that 
infection with one serotype of A. pleuropneumoniae provides complete protection against 
subsequent infection with the homologous serotype and at least partial protection against 
heterologous infection (Nielsen et al., 1984; Haesebrouck et al., 1996).  Preferably, protection 
induced by vaccines should approach protection induced by natural infection.  
The first vaccines that were developed against porcine pleuropneumonia were whole-cell 
bacterins, consisting of inactivated bacterial cell suspensions and supplemented with an 
adjuvant.  Although these vaccines have the advantage of presenting a complex array of 
antigenic determinants to the immune system, inactivation procedures may alter the antigenic 
patterns of a bacterin and may be responsible for the loss of relevant immunogenic epitopes.  
This can be overcome by using ghost vaccines. Bacterial ghosts are empty cell envelopes 
achieved by the expression of a cloned bacteriophage lysis gene and, unlike classical 
bacterins, suffer no denaturating steps during their production.  These properties may lead to 
a superior presentation of surface antigens to the immune system (Hensel et al., 2000).  
Whole-cell bacterins may reduce mortality after infection with the homologous serotype, but 
they generally do not confer protection against challenge with heterologous serotypes.  An 
explanation for the limited protection might be the absence of Apx toxins. Apx toxins are 
indeed thought to be of particular importance for the induction of protective immunity.  Frey 
and Nicolet (1991) reported that Apx toxins are secreted by the bacterium in the culture 
medium and that they are not cell-associated. However, this is in contrast with reports by 
Fedorka-Cray (1989; 1993). Results of our studies also suggest that the Apx toxins are not 
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cell-associated since antibodies against Apx toxins were not detected in sera of animals 
vaccinated with bacterins based on UV-inactivated and washed A. pleuropneumoniae 
bacteria.    
Improved protection has been obtained by using subunit vaccines containing the Apx toxins.  
Among the different serotypes of A. pleuropneumoniae, 4 of these exotoxins have been 
described.  In contrast to ApxI, ApxII and ApxIII toxins, each of which is produced by some 
but not all serotypes, the ApxIV toxin is produced by all serotypes (Cho and Chae, 2001; 
Schaller et al., 1999).  Apparently, the ApxIV toxin is only produced in vivo (Schaller et al., 
1999).  Therefore, the current commercially available vaccines do not contain this ApxIV 
toxin.  Results of the present thesis and field trials demonstrated that vaccination with 
vaccines containing ApxI, ApxII and ApxIII can result in a reduction of the clinical symptoms 
and lung lesions of acute and chronic pleuropneumonia and improvement of performance 
(growth, feed conversion, cost of medication) (Pommier et al., 1996; Valks et al., 1996; 
Martelli et al., 1996; Lopez et al., 1998; Lium et al., 1998).   
Keeping in mind the very complex pathogenesis of porcine pleuropneumonia, inclusion of 
other bacterial virulence factors in subunit vaccines might be of value.  Results of studies 
described in this thesis demonstrated that a vaccine containing both Apx toxins and 
transferrin binding proteins induced better protection against severe challenge than a vaccine 
solely based on Apx toxins.  Recently, it was shown that antibodies induced against purified 
PalA, the most immuno-predominant outer membrane protein of A. pleuropneumoniae, 
aggravated the consequences of an experimental infection and counteracted the protective 
effect of anti-Apx antibodies (van den Bosch and Frey, 2003).  Therefore, care should be 
taken which antigens are included in subunit vaccines.  In whole-cell preparations of bacterial 
cultures, the concentration of PalA may vary depending on the mode of cultivation and 
preparation of the bacteria.  This may be an explanation for the variation in protective efficacy 
of different bacterins.   
Bacterial virulence factors that, most probably, would be very valuable to include in vaccines 
are adhesins.  Indeed, A. pleuropneumoniae first adheres to alveolar epithelial cells before it 
causes lung lesions (Dom et al., 1992).  Antibodies that interfere with adhesion could block 
this first step in the pathogenesis of porcine pleuropneumonia and protect pigs against lung 
infection.  In chapter 3 of this thesis it was shown that a vaccine containing inactivated A. 
pleuropneumoniae bacteria grown under circumstances resulting in high in vitro adhesion 
induced better protection than a vaccine containing inactivated A. pleuropneumoniae bacteria 
grown under circumstances resulting in low in vitro adhesion.   
 
When we started our studies, no reliable adherence model was available to study the way A. 
pleuropneumoniae interacts with alveolar epithelial cells.  The in vitro adherence model 
developed during these studies enabled us to investigate the first interactions between A. 
pleuropneumoniae and the alveolar epithelial cells.  We were also able to pinpoint the 
adherence mechanisms and to characterize some candidate-adhesins. 
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There are different methods for studying bacterial adherence to tissue culture cells: (1) 
Colony count: the cell layer can be lysed with an appropriate detergent which does not affect 
bacterial viability.  Appropriate dilutions are then plated on agar plates for enumeration of cell-
associated bacteria by colony count (Robbins-Browne and Bennett-Wood, 1992).  The 
number of cell-associated bacteria is most commonly expressed as a percentage of the 
original bacterial inoculum. (2) Radioactivity count: bacteria can be labelled with a radioactive 
isotope before investigation by the adhesion assay.  The number of cell-associated bacteria 
can then be measured by lysing the cell monolayer, and measuring the radioactivity of the 
lysate (Dunkle et al., 1986). (3) Enzyme linked immunosorbent assay: the number of cell-
associated bacteria can be quantitated by ELISA, by either using specific antibodies to the 
adherent bacteria followed by enzyme-conjugated secondary antibody, or by using 
biotinylated bacteria and avidin-enzyme as the detecting agent (Ofek et al., 1986). (4) 
Fluorescence flow cytometry, (5) Light and electron microscopy as was used in our studies.  
Microscopic examination has several advantages.  It allows us to determine the pattern of 
adherence of bacteria and the proportion of host cells with adherent bacteria.  Also, an 
estimation of the number of bacteria adherent to each host cell can be made and changes in 
cell morphology as a result of bacterial adherence can be examined (Nataro et al., 1987; 
Zafriri et al., 1989).  
 
Cultured cells provide a simple and easily controlled model for investigating the host-
bacterium interaction.  Cells can be grown under reproducible conditions and only one cell 
type is represented.  Due to the variation in expression of cell surface epitopes known to exist 
between species and tissues/organs, as well as among cells originating from the same tissue 
as a function of developmental and differentiation stages (Falk et al., 1994a; Falk et al., 
1994b), careful consideration must be made to the type of cultured cell selected for the 
adhesion assays.  The cultured cell chosen in these studies, i.e. the alveolar epithelial cell, is 
the naturally colonized cell with which the organism interacts.   
 
The in vitro adhesion model offers a valuable alternative for the use of live animals, in line 
with the Three Rs concept (replacement, reduction and refinement) of Russell & Burch 
(1959).  Any experimental system which does not entail the use of a whole, living animal is 
considered to be a replacement alternative.  The in vitro adhesion model developed here is a 
relative replacement, as it still entails the humane killing of an animal for the purpose of 
obtaining cells for subsequent in vitro studies.  Although animals are needed to collect the 
cells, the animals are used more economically, because a single animal provides cells for a 
number of cultures.  To collect the alveolar epithelial cells, pain and suffering was minimised 
as the animals were anaesthetised and euthanised prior to the collection of the cells.  In that 
way, the animals merely act as organ donors and are not subjected to painful infectivity 
studies.   
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However, there are also disadvantages to the use of in vitro models.  In the in vivo situation, 
the interplay between the alveolar epithelial cells and A. pleuropneumoniae occurs at an air 
interface. Tsang et al. (1994) have described a novel tissue culture model to study the 
interaction of Pseudomonas aeruginosa with adenoid tissue in which bacterial interaction with 
respiratory mucosa occurs in air-mucosal interphase.  Evenso, Jackson et al. (1996) 
compared the interaction of Haemophilus influenzae type b with adenoid tissue cultures 
maintained with an air interface or immersed in medium.  They observed that bacterial 
adhesion to mucus and damaged epithelium was significantly higher in the mucosa-air 
interface model than in immersed tissue cultures.  They concluded that immersion of 
respiratory tissue during experimental infection can substantially influence the results 
obtained.  Moreover, the surfactant layer covering the alveolar epithelial cells in vivo is absent 
in the in vitro adhesion model.  Therefore, data obtained from in vitro experimental models 
should be confirmed in animal models. 
 
In the in vitro adhesion assay, porcine alveolar epithelial cells were allowed to attach to 
coverslips whereafter they were fixed with methanol.  Fixation was used to prevent 
destruction of the alveolar epithelial cells by the Apx toxins of A. pleuropneumoniae (Van de 
Kerkhof et al., 1996).  Another method to prevent cytotoxic effects is fixing the cells in formalin 
(Spencer et al., 1997).  Preliminary studies indicated that A. pleuropneumoniae does not 
adhere to formalin fixed alveolar epithelial cells, most probably because this results in an 
alteration or destruction of receptors on the host cells.  
In our in vitro adhesion studies, strains belonging to the biotype 1-serotypes 2, 5a, 9 and 10 
were used.  These serotypes were selected because they are commonly found in Belgium 
(Hommez et al., 1988; Hommez et al., 1990; Dom et al., 1994).   
Important considerations before performing bacterial adhesion assays are the bacterial 
growth conditions, as they will influence the expression of virulence factors during the course 
of infection.  In general, growth conditions approximating the in vivo environment have been 
found to produce the best results.  A. pleuropneumoniae biotype 1 is NAD-dependent. We 
postulated that extracellular NAD-concentrations in the lumen of the lung alveoli, most 
probably are very low, since, based on molecular weight and charge, it is unlikely that leakage 
of NAD out of normal living cells occurs. This was confirmed by O’Reilly and Niven (2003).  
They determined the concentrations of NAD in the extracellular fluids of pigs, more precisely 
in plasma, tissue fluids, and laryngeal, tracheal and lung washings and found that the levels in 
these extracellular fluids were considerably lower than those found in human erythrocytes and 
in rat tissues. 
Three different growth media were used: a medium containing 0.03% NAD which was defined 
as NAD-rich and two media containing 0.001% NAD which were defined as NAD-restricted. 
For the serotype 5a, 9 and 10 strains, optimal adherence was observed after growth of 
bacterial cells in a NAD-restricted medium (0.001% NAD).  For the serotype 2 strain, 
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adherence was less influenced by the growth conditions.  This indicates that expression of 
adhesins is strain or serotype-dependent. 
 
Mechanisms by which bacteria maintain close proximity to a mucosal surface can be loosely 
categorized as association, adhesion, and invasion according to the degree of intimacy 
between bacterial and mucosal surfaces.  The most intimate form of bacterial-mucosal 
interaction is invasion, wherein bacteria penetrate the mucosal barrier to establish themselves 
within epithelial cells or adjacent stromal tissue.  Association, the least intimate form of 
surface interaction, implies weak, reversible attachment or localization of bacteria along a 
surface (Marschall, 1984). This may be the result of the combined effects of van der Waals 
forces, hydrogen bonds, and ionic and hydrophobic interactions (Jones, 1977).  Adhesion, a 
more intimate form of attachment than association, describes relatively stable, irreversible 
attachment mediated by specialized complementary molecules in a ligand-receptor fashion 
with numerous noncovalent bonds between surfaces of bacteria and substratum (Jones and 
Isaacson, 1983).  This interaction typically occurs between bacterial surface proteins and 
carbohydrate-containing molecules of the cell membrane or glycocalyx (Lark, 1986).  An 
adhesin is any bacterial structure or molecule that mediates adhesion.  Receptors are 
components of the mucosal surface which bind in a complementary fashion with the active 
site of the corresponding adhesin during specific bacterial adhesion.  
In general, irreversible attachment of bacteria to mucosal surfaces is mediated by a variety of 
complex polymers on the bacterial surface. Results of chapter 2 demonstrate that proteins are 
involved in adhesion of A. pleuropneumoniae to alveolar epithelial cells as indicated by a 
decrease in adherence after pretreating the bacteria with heat, pepsin, trypsin, and protease.  
Proteinaceous bacterial adhesins can be divided into those with fimbrial morphology and 
those lacking definite size and shape. 
Fimbriae and pili are morphologic terms used synonymously to denote nonflagellar, 
filamentous appendages that radiate from the bacterial surface.  The filamentous structure of 
most fimbriae is readily apparent on electron microscopy of negatively stained bacterial 
suspensions (Jones and Isaacson, 1983).  Fimbriae are arranged in a polar or peritrichous 
fashion on the bacterial cell and vary in number from a few to several hundred.  
Surface protein adhesins that lack definitive morphology tend to be outer membrane proteins 
or secreted proteins that remain loosely associated with the bacterial surface. Bordetella 
pertussis produces secreted proteins involved in adhesion to cilia of the respiratory epithelium 
(Cowell et al., 1986). Adhesion of Neisseria gonorrhoeae to epithelial cells is mediated not 
only by fimbriae, but also by a group of closely related outer membrane proteins (Swanson, 
1983).  Outer membrane proteins are also involved in the adhesion of A. 
actinomycetemcomitans to epithelial cells (Jacques and Paradis, 1998) and in adhesion of 
Pasteurella multocida to respiratory mucosal surface preparations (Lübke et al., 1994).  For 
Mannheimia haemolytica, it has been proposed that outer membrane proteins may function 
as adhesins in the absence of fimbriae (Confer et al., 1995). 
General discussion 
 118
 
Our studies indicate that both fimbriae and outer membrane proteins might be involved in 
adhesion of A. pleuropneumoniae to alveolar epithelial cells.  Indeed, fimbriae and a 55 kDa 
outer membrane protein were mainly expressed when A. pleuropneumoniae strains were 
grown on media resulting in optimal adherence.   
Proving that a putative adhesin causes the particular biological effect, i.e. adhesion, is not 
easy (Smith, 1983). The main method of strengthening the evidence for causation is to 
neutralize the adherence capacity of intact virulence organisms by specific antibody raised 
against the purified putative determinant. Antibody specificity is crucial.  Monoclonal 
antibodies could be useful in this respect, but although they have been used extensively in 
identifying bacterial surface components, their use in proving causation of biological effect is 
limited (Sparling, 1983).   
Another method is to perform adhesion tests with alveolar epithelial cells that were pre-
incubated with the purified putative adhesins. For purification of fimbriae, these structures 
should first be removed from the bacterial surface.  This can be obtained by mechanical 
disruption (Imberechts et al., 1992; Wu et al., 1995; Van Alphen et al., 1988) or by heat 
treatment (Yoshimatsu et al., 1991).  Since the number of fimbriae observed on A. 
pleuropneumoniae cells is low, it can be expected that purification will not be easy.  Indeed, in 
preliminary studies it was not possible to obtain sufficient amounts of fimbriae after 
mechanical disruption or heat treatment to allow purification (unpublished data).   
DNA technology can also be very useful for proving causation and relevance for virulence 
determinants on bacterial surfaces. 
One aspect of genetic manipulation is the use of mutants.  Mutants lacking the putative 
virulence determinant are compared with the wild type in the appropriate biological test.  
Another aspect of genetic manipulation is the use of gene cloning.  There are many cloning 
strategies, mostly invoking E. coli.  The E. coli clone can be used to demonstrate directly the 
biological activity of the putative determinant and can also produce it.  More importantly, the 
cloned gene can then be reintroduced into deficient strains of the original pathogen, thereby 
confirming the biological property and virulence in vivo.   
 
The fimbriae observed on A. pleuropneumoniae have been identified as type 4 fimbriae 
(Zhang et al., 2000).  This is according to the classification scheme by Duguid et al. (1966).  
Type 1 refers to fimbriae that are rigid and exhibit mannose-sensitive hemagglutination; type 
2 is serologically related to type 1 but does not cause hemagglutination; type 3 refers to 
mannose-resistant, flexible fimbriae common in Enterobacteriaceae; type 4 are fimbriae 
possessing N-methylphenylalanine in the amino terminus region of the major subunit; and 
type 5 are mannose sensitive, thinner than type 1, and usually few in numbers per cell.  Type 
4 fimbriae have been described in several other Gram-negative bacteria including 
Haemophilus influenzae, Moraxella bovis, Dichelobacter nodosus, Haemophilus ducreyi, 
Pasteurella multocida and Pseudomonas aeruginosa. It has been shown that they mediate 
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attachment of these bacteria to epithelial cells in vivo and in vitro (Sato and Okinaga, 1987; 
Doig et al., 1988; Paranchyn and Frost, 1988; Starr et al., 1999).   
Recently, Stevenson et al. (2003) reported the identification and characterization of the type 4 
fimbrial structural gene (apfA) of A. pleuropneumoniae.  In addition a number of open reading 
frames were identified that have significant homology to type 4 fimbrial biogenesis genes from 
other species.  These type 4 fimbrial biogenesis genes showed the strongest homology to 
putative type 4 fimbrial genes of Haemophilus ducreyi.  Recombinant fimbriae produced by 
expressing type 4 subunits from Moraxella bovis (Beard et al., 1990) and Dichelobacter 
nodosus (Elleman et al., 1986) in Pseudomonas aeruginosa have been used as vaccine 
antigens and this type of approach might be interesting for an A. pleuropneumoniae ApfA 
based vaccine.  Furthermore, it was shown by Boekema et al. (2003) that contact with 
epithelial cells is a trigger for fimbriae production and that there is an in vivo induced activity 
of the fimbriae promoter shortly after infection, suggesting that fimbriae play a role in the 
colonisation and the pathogenesis. 
 
Surface hydrophobicity of bacteria is an important physical factor for adhesion, especially 
when the substrata are either hydrophilic or hydrophobic.  Generally, bacteria with 
hydrophobic properties prefer materials with hydrophobic surfaces, those with hydrophilic 
characteristics prefer hydrophilic surfaces (Hogt et al., 1983; Satou et al., 1988; 
Vacheethasanee et al., 1998).  To assess the role of hydrophobic interactions in adherence, 
we studied the influence of the presence of the hydrophobic bond-breaking agent 
tetramethylurea. This technique was also used by Bélanger et al. (1994) in relation to A. 
pleuropneumoniae adherence to crude mucus.  Hydrophobic interactions did not seem to 
participate in the binding of A. pleuropneumoniae to alveolar epithelial cells in vitro since 
tetramethylurea had no effect on binding. 
 
Many adhesins act as lectins, recognizing specific carbohydrate moieties on host cell 
surfaces. Therefore, bacterial cells were subjected to treatments with various sugars to 
determine whether carbohydrate-specific lectins on the surface of A. pleuropneumoniae cells 
are involved in adherence.  The various sugars we used were mono-and disacharides. The 
finding that none of these sugars caused decreased adherence does not mean that A. 
pleuropneumoniae can not interact with specific carbohydrates in adherence processes. 
Indeed, adhesins can recognize complex carbohydrates as has been described for the P 
fimbriae of Escherichia coli.  These fimbriae recognize complex carbohydrates such as 
globotriasoylceramide and globoside (Bock et al., 1985). Moreover, it can not be excluded 
that different types of lectins are present on the bacterial cells or that a heterogeneous 
population of bacterial cells is present, each bearing a different lectin (Ofek and Sharon, 
1990).  In such cases, a combination of sugars is a more effective inhibitor than individual 
ones.  This, however, remains to be tested.  
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Treatment of A. pleuropneumoniae strains with sodium metaperiodate resulted in decreased 
adhesion of the bacteria to alveolar epithelial cells, but inhibition was clearly lower than after 
treatment of bacteria with proteolytic enzymes.  The finding that inhibition of adhesion was 
very high when bacteria were treated with a combination of sodium metaperiodate and 
pronase suggests that more than one adhesin is involved.  Indeed, although adhesion of 
bacteria to host cells may depend on the binding of a unique bacterial adhesin to a unique 
host receptor, most frequently bacterial adhesion depends on simultaneous interaction 
between multiple adhesins with different cell receptors.  The inhibition of a single pathway 
therefore may have no effect on overall adhesion or at best may produce a partial inhibition.  
Most Pasteurellaceae organisms can employ multiple molecular mechanisms of adherence to 
initiate infection (Jacques and Paradis, 1998).  Proteins (e.g. fimbriae, fibrils, outer membrane 
proteins) and/or polysaccharides were shown to play a role in adherence of several members 
of this bacterial family.  These multiple adhesins may be used in a stepwise fashion during 
colonization.  It seems reasonable that evolutionary pressures have selected organisms that 
are capable of using more than one mechanism of adherence (Ofek and Doyle, 1994).   
 
As stated before, it is very important to confirm data obtained from in vitro models in animal 
models.  This was certainly recommended in our studies because the surfactant layer 
covering the alveolar epithelial cells in vivo is absent in the in vitro adhesion model.  
Pulmonary surfactant is a lipoprotein complex that is synthesized and secreted by the alveolar 
type II epithelial cell and the airway Clara cell (Gourke, 1998). Once in the extracellular space, 
surfactant reduces surface tension at the air-liquid interface of the lung, a function that 
requires an appropriate mix of surfactant lipids and the hydrophobic proteins, surfactant 
protein B (SP-B) and SP-C (Whitsett, 1995).   Phospholipids of several types are the major 
components of surfactant.  Phospholipids are amphipathic molecules with a polar head group 
and a nonpolar tail.  These hydrophobic tails are extended into the air.  The single most 
abundant phospholipid is dipalmitoylphosphatidylcholine (Hawgood, 1991).  Other 
phospholipids are: unsaturated phosphatidylcholines, phosphatidylglycerol, 
phosphatidylethanolamine and phosphatidylserine.  It is possible that A. pleuropneumoniae 
interacts with surfactant as a first step in the colonization.  We demonstrated that A. 
pleuropneumoniae binds to surfactant proteins.  Moreover, in vivo adhesion studies resulted 
in adherence of A. pleuropneumoniae to lung alveoli irrespective of the growth conditions of 
the bacteria.  This was in contrast with the in vitro adhesion studies whereby growth on NAD 
restricted media resulted in significantly higher adhesion scores in serotype 5, 9 and 10 
strains.  Hydrophobicity tests as described by Vercauteren et al. (1993) did not show 
differences in hydrophobicity between bacteria grown under different growth conditions 
(unpublished results).  All these results indicate that adhesion of A. pleuropneumoniae to 
alveoli is a two step adhesion.  A first step could be a reversible association of A. 
pleuropneumoniae with surfactant.  Lipopolysaccharides might be involved in this association 
since Jeannotte et al. (2003) described that A. pleuropneumoniae can bind to 
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phosphatidylethanolamine.  Such association has also been described for other pathogenic 
bacteria including Chlamydia pneumoniae and Chlamydia trachomatis (Krivan et al., 1991), 
Helicobacter pylori (Lingwood et al., 1992), Helicobacter mustelae (Gold et al. 1993), 
Haemophilus influenzae (Busse et al., 1997) and Campylobacter upsaliensis (Busse et al., 
1997).   
A second step could be an adhesion step to alveolar epithelial cells i.e. a relatively stable, 
irreversible attachment mediated by specialized complementary molecules in a ligand-
receptor fashion.   The above described candidate-adhesins i.e. fimbriae and a 55 kDa outer 
membrane protein could play a role in this adhesion.   
 
Surfactant also plays a role in host defence against infection and inflammation (Wright, 
1997&2003). Two of the surfactant proteins, SP-A and SP-D, are members of the collectin 
protein family (Crouch and Wright, 2001; Crouch et al., 2000).  The most well-defined function 
of the collectins is their ability to opsonize pathogens, including bacteria and viruses, and to 
facilitate phagocytosis by innate immune cells such as macrophages and monocytes. It is 
unlikely that opsonization of A. pleuropneumoniae and subsequent phagocytosis by 
macrophages and monocytes will result in killing of A. pleuropneumoniae.  Indeed, Cruijsen et 
al. (1992) demonstrated that porcine alveolar macrophages effectively phagocytise virulent 
strains of A. pleuropneumoniae in the presence of convalescent pig serum but they are not 
able to kill the bacteria intracellularly.  This is most probably due to intracellular released Apx 
toxins (Cruijsen et al., 1992).  Data presented by Wu and coworkers (2003) show convincingly 
that, in addition to facilitating pathogen uptake and killing by immune cells, SP-A and SP-D 
are directly antimicrobial, that is, they kill bacteria in the absence of immune effector cells.  
The effect of these surfactant proteins on A. pleuropneumoniae has not yet been studied. 
 
In conclusion, results of the present thesis confirm that the currently available subunit 
vaccines, based on Apx toxins, induce partial protection.  Inclusion of adhesins in such 
vaccines might improve efficacy.  Adhesion of A. pleuropneumoniae to alveolar epithelial cells 
is a very complex phenomenon and several bacterial antigens seem to be involved including 
outer membrane proteins and fimbriae.  Additional studies are necessary to further 
characterize virulence factors responsible for adhesion of A. pleuropneumoniae to host cells. 
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SUMMARY 
 
A. pleuropneumoniae causes severe losses in the pig rearing industry.  Although the disease 
can be controlled by antimicrobial agents, the use of these products has several 
disadvantages including induction of acquired resistance in pathogenic bacteria and bacteria 
belonging to the normal flora of pigs.  Therefore, prevention instead of therapy is an 
increasing requirement in the control of the disease.  Vaccines could be very useful to control 
porcine pleuropneumonia.  Rational design of effective antibacterial vaccines, however, 
requires knowledge of the virulence factors of the bacterium and the pathogenesis of the 
disease.  Pathogenesis of porcine pleuropneumonia is very complex and several virulence 
factors have been described.  Some of these virulence factors, such as the Apx toxins, have 
been extensively studied.  Virulence attributes involved in lung colonisation are, however, less 
well known.  The need for research in these first steps of pathogenesis provided the main 
rationale for this thesis. 
 
The experiments performed in this thesis are divided in 3 Chapters.  In Chapter 1, the efficacy 
of vaccines containing Apx toxins was evaluated. Thereafter, the adhesion of A. 
pleuropneumoniae to porcine alveolar epithelial cells in vitro and in vivo was studied (Chapter 
2).  Finally, the efficacy of a vaccine containing candidate-adhesins was evaluated (Chapter 
3). 
 
In a first study described in Chapter 1, the efficacy of two inactivated vaccines containing the 
Apx toxins of Actinobacillus pleuropneumoniae (Hemopig™, Biokema, Lausanne, Switzerland 
and Porcilis™ App, Intervet, Boxmeer, The Netherlands) was determined.  Therefore, ten pigs 
were vaccinated twice with Hemopig™ and eight pigs with Porcilis™ App.  Ten control 
animals were injected twice with a saline solution.  Three weeks after the second vaccination, 
all pigs were endobronchially inoculated with 10
5
 colony-forming units (CFU) of an A. 
pleuropneumoniae serotype 9 strain.  Increased respiratory rate and/or fever were observed 
in all vaccinated and control pigs after challenge.  One pig of the Hemopig™ group and of the 
Porcilis™ App group died, whereas all pigs of the control group survived the challenge.  
Surviving pigs were killed at 7 days after challenge.  The mean percentage of affected lung 
tissue was 34% in the control group, 16% in the Hemopig™ group, and 17% in the Porcilis™ 
App group.  A. pleuropneumoniae was isolated from the lungs of all 10 control animals, from 7 
of the 10 animals vaccinated with Hemopig™ and from 5 of the 8 animals vaccinated with 
Porcilis™ App.  The mean bacterial titres of the caudal lung lobes were 1.4x10
6
 CFU/g in the 
control group, 1.7x10
3
 CFU/g in the Hemopig™ group, and 4.8x10
3
 CFU/g in the Porcilis™ 
App group.  In both vaccinated groups the mean number of days with dyspnoea, the mean 
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number of days with fever, the mean percentage of affected lung tissue, and the mean 
bacterial titre in the caudal lung lobes were significantly lower than in the control group.  
Significant differences between the two vaccinated groups were not observed.  It was 
concluded that both vaccines induced partial protection. 
 
In a second study, the efficacy of a subunit vaccine containing the Apx toxins and transferrin 
binding proteins was determined. Therefore, ten pigs were vaccinated twice with the vaccine.  
Eight control animals were injected twice with a saline solution.  Three weeks after the second 
vaccination, all pigs were endobronchially inoculated with 10
6.5
 colony-forming units (CFU) of 
an A. pleuropneumoniae serotype 9 strain.  In the vaccine group, none of the pigs died after 
inoculation.  Only one pig of the control group survived challenge.  Surviving pigs were killed 
at 7 days after challenge.  The mean percentage of affected lung tissue was 64% in the 
control group and 17% in the vaccine group.  A. pleuropneumoniae was isolated from the 
lungs of all animals.  The mean bacterial titres of the caudal lung lobes were 5.0x108 CFU/g in 
the control group and 3.0x106 CFU/g in the vaccine group.  It was concluded that the vaccine 
induced partial protection against severe challenge. 
 
Keeping in mind the very complex pathogenesis of porcine pleuropneumonia, inclusion of 
other bacterial virulence factors in subunit vaccines might be of value.  Bacterial virulence 
factors that, most probably, would be very valuable to include in vaccines are adhesins.  
Indeed, A. pleuropneumoniae first adheres to alveolar epithelial cells before it causes lung 
lesions.  Antibodies that interfere with adhesion could block this first step in the pathogenesis 
of porcine pleuropneumonia and protect pigs against lung infection. Therefore, the adhesion 
of A. pleuropneumoniae to cells in vitro and in vivo was studied (Chapter 2).   
In a first study, the adhesion ability of A. pleuropneumoniae biovar 1 serotype 2, 5a, 9 and 10 
strains was tested to alveolar epithelial cells in culture.  For the serotype 5a, 9 and 10 strains, 
optimal adherence was observed after growth of bacterial cells in a NAD-restricted medium 
(0.001% NAD).  This condition was also associated with the expression of a 55 kDa outer 
membrane protein and of fimbriae.  For the serotype 2 strain, adherence and expression of 
fimbriae and a 55 kDa outer membrane protein was less influenced by the growth conditions.  
The N-terminal amino acid sequence of the 55 kDa outer membrane protein had no homology 
with any known sequence, suggesting that it is an as yet unknown protein.  Adherence 
capabilities were significantly reduced following treatment of the bacteria with proteolytic 
enzymes or heat.  These findings suggest that proteins are involved in adhesion.  The 
hydrophobic bond breaking agent tetramethylurea was unable to inhibit the adherence of A. 
pleuropneumoniae to alveolar epithelial cells.  Treatment of the bacteria with sodium 
metaperiodate resulted in lower adhesion scores for the serotype 2 and 9 strains but the 
inhibition of adhesion was clearly lower than after treatment with proteolytic enzymes.  This 
indicates that, besides proteins, carbohydrates might also be involved in adhesion of A. 
pleuropneumoniae to alveolar epithelial cells. The finding that inhibition of adhesion was very 
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high when bacteria were treated with a combination of sodium metaperiodate and pronase 
also suggests that more than one adhesin is involved.  
 
Secondly, the effect of culture conditions on adhesion of inactivated A. pleuropneumoniae 
biotype 1-serotype 2 and 9 strains to alveoli of experimentally inoculated piglets was studied.  
Growing the bacteria on a NAD-restricted or NAD-rich medium did not influence this adhesion 
and had no effect on the in vitro association of the bacteria with surfactant proteins.  Adhesion 
scores in alveolar epithelial cell cultures were, however, much higher when the serotype 9 
strain was grown on the NAD-restricted medium.  It is possible that different adhesins are 
involved in colonisation of alveoli of infected pigs.  Association with surfactant might be a first 
step that precedes adhesion to alveolar epithelial cells. 
 
Finally, in Chapter 3, the efficacy of two bacterins containing an A. pleuropneumoniae 
serotype 10 strain was evaluated.  The bacterial cells constituting bacterin 1 and 2 were 
grown under NAD-rich (low adherence capacitiy to alveolar epithelial cell cultures) and NAD-
restricted (high adherence capacity to alveolar epithelial cell cultures) conditions, respectively.  
Ten pigs were vaccinated twice with the bacterin 1 and 9 pigs with the bacterin 2.  Ten control 
animals were injected twice with a saline solution.  Three weeks after the second vaccination, 
all pigs were endobronchially inoculated with 106.5 colony-forming units (CFU) of an A. 
pleuropneumoniae serotype 10 strain.  In the bacterin 1 and 2 group, three and two pigs died 
after inoculation, respectively.  Only two pigs of the control group survived challenge.  
Surviving pigs were killed at 7 days after challenge.  The percentage of pigs with severe lung 
lesions (>10% of the lung affected) was 100% in the control group, 70% in the bacterin 1 
group and 22% in the bacterin 2 group.  A. pleuropneumoniae was isolated from the lungs of 
all animals.  The mean bacterial titres of the caudal lung lobes were 7.0x106 CFU/g in the 
control group, 6.3x105 CFU/g in the bacterin 1 group and 1.3x106 CFU/g in the bacterin 2 
group.  It was concluded that both bacterins induced partial protection against severe 
challenge.  Furthermore, there are indications that the bacterin 2, containing A. 
pleuropneumoniae bacteria grown under conditions resulting in high in vitro adhesion, 
induced better protection than the bacterin 1.   
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SAMENVATTING 
A. pleuropneumoniae veroorzaakt grote economische verliezen in de varkenshouderij.  Bij de 
bestrijding van pleuropneumonie wordt vaak gebruik gemaakt van antibiotica.  Alhoewel 
antibiotica hun nut bewezen hebben, zijn er aan het overvloedig gebruik ervan verschillende 
nadelen verbonden zoals het optreden van verworven resistentie.  Het is duidelijk dat dient 
gezocht te worden naar alternatieve bestrijdingsstrategiën.  Hierbij wordt in de eerste plaats 
gedacht aan vaccinatie.  Bij de ontwikkeling van effectieve antibacteriële vaccins, is een 
grondige kennis van de virulentiefactoren van de kiem en de pathogenese van de ziekte 
noodzakelijk.  De pathogenese van pleuropneumonie is zeer complex en er werden reeds 
verschillende virulentiefactoren beschreven.  Sommige van deze virulentiefactoren, zoals de 
Apx toxines, werden in detail bestudeerd.  Virulentiefactoren die betrokken zijn in de 
kolonisatie van de long zijn echter minder gekend.  Onderzoek naar deze eerste stappen in 
de pathogenese was dan ook het hoofdobjectief van dit proefschrift.    
 
Het experimentele gedeelte van dit proefschrift wordt in 3 hoofdstukken ingedeeld.  Vooreerst 
werd de doeltreffendheid van vaccins die Apx toxines bevatten, bepaald.  Daarna werd de 
adhesie van A. pleuropneumoniae aan alveolaire epitheelcellen in vitro en in vivo bestudeerd 
(Hoofdstuk 2).  Tenslotte werd de doeltreffendheid bepaald van een vaccin dat kandidaat-
adhesines bevat (Hoofdstuk 3). 
 
In een eerste studie die beschreven werd in Hoofdstuk 1, werd de efficaciteit bepaald van 
twee geïnactiveerde vaccins die de Apx toxines van A. pleuropneumoniae bevatten 
(Hemopig™ Biokema, Lausanne, Zwitserland en Porcilis™ App, Intervet, Boxmeer, 
Nederland).  Hiertoe werden 10 varkens tweemaal, met een interval van 3 weken ingespoten 
met Hemopig™ en 8 varkens werden tweemaal, met een interval van 3 weken gevaccineerd 
met Porcilis™ App.  Tien andere biggen werden met een gebufferde zoutoplossing op 
analoge wijze geïnoculeerd en dienden als controles.  Drie weken na de tweede vaccinatie 
werden alle dieren endobronchiaal geïnoculeerd met 105 kolonie-vormende eenheden (kve) 
van een A. pleuropneumoniae serotype 9 stam.  Alle dieren werden klinisch gevolgd.  Dieren 
die overleefden, werden 7 dagen na de inoculatie geëuthanaseerd.  Een verhoogde 
ademhalingsfrequentie en/of koorts kon worden waargenomen bij alle gevaccineerde dieren 
en controledieren.  Alle controledieren overleefden de besmetting.  Zowel in de Hemopig™ 
groep als de Porcilis™ App groep stierf er 1 dier na de besmetting.  Het gemiddeld 
percentage aangetast longweefsel bedroeg 34% in de controlegroep, 16% in de Hemopig™ 
groep en 17% in de Porcilis™ App groep.  A. pleuropneumoniae kon uit de longen van alle 
controledieren geïsoleerd worden en de gemiddelde bacteriële titer in de caudale 
longkwabben bedroeg 1.4x106 kve/gram.  Bij de Hemopig™ groep kon A. pleuropneumoniae 
bij 7 van de 10 dieren geïsoleerd worden en de gemiddelde bacteriële titer bedroeg 1.7x103 
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kve/gram.  Bij de Porcilis™ App groep kon A. pleuropneumoniae bij 5 van de 8 dieren 
geïsoleerd worden en de gemiddelde bacteriële titer bedroeg 4.8x103 kve/gram.  In beide 
vaccingroepen was het gemiddeld aantal dagen met dyspnee, het gemiddeld aantal dagen 
met koorts, het gemiddeld percentage aangetast longweefsel en de gemiddelde bacteriële 
titer in de caudale longkwabben significant lager dan bij de controlegroep.  Er werden geen 
significante verschillen gevonden tussen de 2 vaccingroepen.  Er werd geconcludeerd dat 
beide vaccins partiële bescherming induceerden. 
 
In een tweede studie werd de doeltreffendheid bepaald van een vaccin dat niet alleen Apx 
toxines maar ook transferrine bindende proteïnes bevat.  Hiertoe werden 10 dieren tweemaal 
gevaccineerd met het vaccin met een interval van 4 weken.  Acht controledieren werden 
tweemaal ingespoten met een gebufferde zoutoplossing.  Drie weken na de tweede 
vaccinatie werden alle dieren endobronchiaal geïnoculeerd met 106.5 kolonie-vormende 
eenheden (kve) van een A. pleuropneumoniae serotype 9 stam.  In de vaccingroep stierf 
geen enkel dier.  Slechts 1 dier overleefde de besmetting in de controlegroep.  De dieren die 
de besmetting overleefden, werden na 7 dagen geëuthanaseerd.  Het gemiddeld percentage 
aangetast longweefsel bedroeg 64% in de controlegroep en 17% in de vaccingroep.  A. 
pleuropneumoniae kon uit de longen van alle dieren geïsoleerd worden.  De gemiddelde 
bacteriële titers in de caudale longkwabben bedroeg 5.0x108 kve/gram bij de controlegroep 
en 3.0x106 kve/gram bij de vaccingroep.  Er werd geconcludeerd dat het vaccin partiële 
bescherming induceerde tegen een ernstige besmetting. 
 
Aangezien de pathogenese van pleuropneumonie zeer complex is, kan het insluiten van 
andere bacteriële virulentiefactoren in subunit vaccins waardevol zijn.  Hierbij kan zeker 
gedacht worden aan adhesines.  Het is immers zo dat A. pleuropneumoniae zich vasthecht 
aan de alveolaire epitheelcellen vooraleer er longletsels ontstaan.  Aanwezigheid van 
antistoffen die deze adhesie verhinderen, zouden de eerste stap in de pathogenese kunnen 
blokkeren en het dier beschermen tegen longinfectie.  Om deze reden werd de adhesie van 
A. pleuropneumoniae aan alveolaire epitheelcellen in vitro en in vivo bestudeerd (Hoofdstuk 
2). 
In een eerste studie werd de adhesie van A. pleuropneumoniae biovar 1 serotype 2, 5a, 9 en 
10 aan in vitro culturen van alveolaire epitheelcellen onderzocht.  Voor de serotypes 5a, 9 en 
10 stammen kon een optimale adhesie slechts bekomen worden wanneer de kiemen werden 
opgegroeid op een NAD-arm milieu (0.001% NAD).  Deze groeicondities waren ook 
gerelateerd met de expressie van een 55 kDa buitenste membraan eiwit en fimbriae.  Voor de 
serotype 2 stam waren adhesie en expressie van de fimbriae en het 55 kDa buitenste 
membraan eiwit minder afhankelijk van de groeicondities.  De N-terminale aminozuur 
sequentie van het 55 kDa buitenste membraan eiwit werd bepaald en er werd geen 
homologie gevonden met andere gekende sequenties.  Dit duidt erop dat het hier gaat om 
een tot nu toe ongekend eiwit.  De adhesie capaciteit van de kiemen was significant lager na 
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behandeling van de bacteriën met proteolytische enzymes of hitte.  Deze bevindingen 
suggereren dat eiwitten betrokken zijn in de adhesie.  Behandeling met tetramethylureum, 
een product dat hydrofobe verbindingen verbreekt, kon de adhesie niet inhiberen.  
Behandeling van de bacteriën met natriummetaperiodaat resulteerde in lagere adhesiescores 
voor de serotype 2 en 9 stammen maar de inhibitie was duidelijk lager dan de inhibitie 
bekomen na behandeling met proteolytische enzymes.  Dit duidt erop dat, naast eiwitten, ook 
suikers een rol spelen in de adhesie van A. pleuropneumoniae aan alveolaire epitheelcellen.  
Het feit dat behandeling van de bacteriën met een combinatie van natriummetaperiodaat en 
pronase resulteerde in de hoogste inhibitie suggereert eveneens dat er meer dan één 
adhesine betrokken is. 
 
In een tweede studie werd het effect bestudeerd van de cultuurcondities op adhesie van 
geïnactiveerde A. pleuropneumoniae biotype 1-serotype 2 en 9 stammen aan de alveolen van 
experimenteel besmette biggen.  Er kon geen verschil in adhesie gevonden worden tussen 
bacteriën die opgegroeid waren op een NAD-arm of een NAD-rijk medium.  Deze 
groeicondities hadden ook geen effect op de in vitro associatie van de bacteriën met 
surfactant eiwitten. Het is mogelijk dat verschillende adhesines betrokken zijn in de 
kolonisatie van de alveolen bij geïnfecteerde varkens.  In een eerste stap zouden de kiemen 
zich kunnen associëren met surfactant.  Daarna zou een meer stabiele adhesie aan 
alveolaire epitheelcellen kunnen optreden. 
 
Tenslotte werd de doeltreffendheid van twee bacterins die een A. pleuropneumoniae serotype 
10 stam bevatten, nagegaan (Hoofdstuk 3).  Bacterin 1 bestond uit bacteriën die opgegroeid 
waren in een NAD-rijk milieu (lage adhesie capaciteit aan alveolaire epitheelcelculturen), 
bacterin 2 uit bacteriën die opgegroeid waren in een NAD-arm milieu (hoge adhesie capaciteit 
aan alveolaire epitheelcelculturen).  Tien dieren werden tweemaal gevaccineerd met het 
bacterin 1 en 9 dieren tweemaal met het bacterin 2, telkens met een interval van 3 weken.  
Tien controledieren werden tweemaal ingespoten met gebufferde zoutoplossing.  Drie weken 
na de tweede vaccinatie werden alle dieren endobronchiaal geïnoculeerd met 106.5 kolonie-
vormende eenheden (kve) van een A. pleuropneumoniae serotype 10 stam. Drie dieren van 
de bacterin 1 groep en 2 dieren van de bacterin 2 groep stierven na de besmetting.  Slechts 2 
van de controledieren overleefden de besmetting.  De dieren die de besmetting overleefden, 
werden na 7 dagen geëuthanaseerd.  Het percentage dieren met erge longletsels (>10% van 
de long aangetast) bedroeg 100% bij de controlegroep, 70% bij de bacterin 1 groep en 22% 
bij de bacterin 2 groep.  A. pleuropneumoniae kon uit de longen van alle dieren geïsoleerd 
worden.  De gemiddelde bacteriële titer in de caudale longkwabben bedroeg 7.0x106 
kve/gram bij de controlegroep, 6.3x105 kve/gram bij de bacterin 1 groep en 1.3x106 kve/gram 
bij de bacterin 2 groep.  Er werd geconcludeerd dat beide bacterins een partiële bescherming 
bieden tegen een ernstige besmetting.  Bovendien waren er indicaties dat het bacterin 2, dat 
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A. pleuropneumoniae kiemen bevat opgegroeid onder condities die resulteerden in hoge in 
vitro adhesie, een betere bescherming geeft dan het bacterin 1. 
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DANKWOORD 
“Anyone who has never made a mistake has never tried anything new” 
-Albert Einstein- 
 
 
 
In de eerste plaats wil ik mijn promoter, Prof. Dr. F. Haesebrouck, bedanken voor zijn 
begeleiding, geduld en aansporingen tijdens deze studies.  Professor, uw vele nuttige 
discussies, ideeën en contacten waren onontbeerlijk in dit onderzoek.  U was altijd bereid een 
luisterend oor te bieden en ons te motiveren verder te experimenteren.  De geur van de 
varkentjes kon u bovendien altijd verblijden; en dat is niet zo evident...Nogmaals bedankt voor 
het vertrouwen dat u in mij stelde en voor de aanmoedigingen die geleid hebben tot dit 
proefschrift. 
Prof. Dr. R. Ducatelle, mijn co-promotor, zou ik willen bedanken voor de vele vernieuwende 
ideeën en zijn welgekend enthousiasme.  Professor, uw opmerkingen en vragen deden ons 
wat kritischer naar ons werk kijken.  Het was zeer aangenaam met u samen te werken, 
bedankt.  
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waarvoor dank.  Dergelijke bijdragen zijn van essentieel belang, niet enkel voor de economie, 
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worden verder gezet.  In het bijzonder wil ik Ir. J. Weerts en Dr. X. Van Huffel graag 
bedanken voor hun vertrouwen in ons onderzoek en de begeleiding van het project.   
 
Mijn dank gaat ook uit naar alle leden van de begeleidingscommisie: Prof. Dr. M. Pensaert, 
Prof. Dr. P. Deprez, Prof. Dr. J. Mainil en Prof. Dr. H. De Greve voor hun constructieve 
opmerkingen die de kwaliteit en de wetenschappelijke waarde van dit proefschrift zeker ten 
goede zijn gekomen. 
 
De verschillende studies van deze thesis waren slechts mogelijk door de hulp van talrijke 
mensen waaronder de heer G. Charlier, Dr. L. Devriese, Prof. Dr. F. Gasthuys.  Ook de 
mensen werkzaam aan de Vakgroep Pathologie, Bacteriologie en Pluimveeziekten mogen 
hierbij niet vergeten worden. Zij zorgden voor een aangename sfeer in de laboratoria en 
omgeving.  Voornamelijk diegenen die werkzaam waren op de APP projecten verdienen een 
extra bedanking: N. Van Loocke, S. Mekeirle, N. Van Rijsselberghe, D. D’Halluin, G. 
Massaer, J. Decraene, E. Verleysen, L. Hautekeete. We konden altijd rekenen op jullie hulp 
en inzet om het App’tje en de OMP’tjes aan te pakken.  Laboratoriumwerk, varkenswerk, 
veldwerk, alles is de revue gepasseerd.  Jullie waren bovendien altijd bereid om om het even 
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wat uit te proberen, ook als het soms wat tegenviel.  Ook voor jullie geldt dan ook een dikke 
proficiat met jullie werk dat resulteert in dit proefschrift.  Ik wens jullie nog veel geluk toe in 
jullie verdere leven.  Ook C. Puttevils wil ik nog eens extra bedanken voor het maken van de 
vele coupes. 
 
Dr. J. Jourquin en Dr. W. Neirynck van de firma Ratllerow Seghers zorgden ervoor dat wij 
altijd konden rekenen op het leveren van de geschikte biggetjes, waarvoor dank. 
 
Bovendien wil ik ook nog alle varkentjes die zich opgeofferd hebben voor deze studies 
bedanken.  Zonder hen was het hetzelfde niet... Proeven uitvoeren met levende dieren is niet 
altijd evident.  Het is altijd zoeken naar een evenwicht tussen wetenschappelijke correctheid 
en ethische correctheid.  Ik hoop dan ook dat de resultaten van deze studies zullen leiden tot 
een vooruitgang in de bestrijding van pleuropneumonie in de varkenssector. Ook hun 
verzorgers Magda en Gilbert verdienen een pluimpje.  Zij zorgden ervoor dat de dieren alles 
kregen wat nodig was.  Bovendien kregen zij de stallen keer op keer kraaknet en dat is een 
hele prestatie. 
 
En dan ook nog deze mensjes: 
 
Koen Chiers en Eef Donné (ons ‘Beefie’) voor de vele uurtjes die we samen doorbrachten in 
onze toren en bij onze beesten.  Koen, bedankt dat ik altijd bij jou terecht kon met mijn vele 
vragen.  Kooeeennn...was een veelgehoorde uitroep voor jouw hulp.  Jij hebt me wegwijs 
gemaakt in het kluwen van de App beestjes en in het werk met de varkens.  Beefie, ook 
bedankt voor alles!  Lief en leed werd gedeeld daarboven en ik kon altijd rekenen op jullie 
hulp en raad.  We hebben samen vele uren doorgebracht met onze kleine en grote beesten 
en daarbij hebben we zeker ook goed gelachen.  Bedankt allebei voor jullie hulp, steun en 
vriendschap in goede en minder goede tijden.  Ik ben ervan overtuigd dat dit proefschrift er 
niet zou zijn zonder jullie hulp.   
 
Anneleen Van Acker en Sofie Taghon.  Goeie vriendinnetjes... 
 
Natuurlijk ook de vele vrienden en familie voor hun steun en interesse tijdens de afgelopen 
jaren.  Pepe, spijtig dat je er niet bij kan zijn.  Ik weet zeker dat je trots op mij zou geweest 
zijn. 
 
Mijn lieve ouders.  Zonder jullie hulp en steun zou dit proefschrift er niet zijn.  Jullie gaven me 
de gelegenheid mijn dierenliefde te volgen; een gegeven waar het allemaal mee begon.  
Jullie hebben mij altijd aangemoedigd, zowel in mijn studies als tijdens de ‘werkjaren’.   Moe 
en pa, ik hoop dat jullie nu wat beter begrijpen waarmee ik al die jaren bezig was.  Ook 
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bedankt voor de ‘logistieke’ steun in ons huishouden, voor het verzorgen van Oribie en voor 
het passen op Hanna en Wolfje.     
 
En...natuurlijk ook mijn lievelingen Niek, Hanna en Wolf... 
If not for you, 
Babe, I couldn't find the door, 
Couldn't even see the floor, 
I'd be sad and blue, 
If not for you. 
 
If not for you, 
Babe, I'd lay awake all night, 
Wait for the mornin' light 
To shine in through, 
But it would not be new, 
If not for you. 
 
If not for you 
My sky would fall, 
Rain would gather too. 
Without your love I'd be nowhere at all, 
I'd be lost if not for you, 
And you know it's true. 
 
If not for you 
My sky would fall, 
Rain would gather too. 
Without your love I'd be nowhere at all, 
Oh! What would I do 
If not for you. 
 
If not for you, 
Winter would have no spring, 
Couldn't hear the robin sing, 
I just wouldn't have a clue, 
Anyway it wouldn't ring true, 
If not for you. 
 
-Bob Dylan- 
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